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ABSTRACT 
 
Pneumothorax, or a collapsed lung, is a serious medical condition resulting 
when air or fluid escapes the lung into the chest cavity and prevents the lung from 
inflating. Few viable means of sealing the damaged and leaking tissues are currently 
available, leading to longer hospital stays, multiple interventions, and increasing costs of 
care. The motivation of this dissertation is to engineer a novel polysaccharide-based 
therapeutic surgical sealant, which can be utilized to seal trauma-induced damage to the 
outer lining of the lung, i.e. pleura, preventing or reversing lung collapse to restore 
normal breathing function.  
 
The use of polysaccharides, such as alginate and hyaluronan, has become 
increasingly prevalent in biomedical and tissue engineering applications due to the ability 
to add functionality through chemical modification, allowing for tunable mechanical and 
physical properties. These hydrophilic polymer chains can be crosslinked to form 
hydrogels, which can retain large volumes of water and can mimic the properties of 
tissues found within the body. In this work, polysaccharide hydrogel sealants were 
engineered with well-regulated gelation and mechanical properties, and further modified 
to achieve adhesion to biological tissues. This was accomplished by mimicking the 
mechanical and physical properties of the complex tissues, and crosslinking the hydrogels 
in situ using a visible light-initiated system.  
 
Methacrylated alginate and oxidized alginate were successfully synthesized and 
utilized to fabricate adhesive sealant patches, which can adhere and seal damaged tissues 
in vivo. Methacrylation was implemented to allow covalent photo-crosslinking between 
adjacent polymer chains in solution. Here, a novel anhydrous chemistry was developed to 
allow for precise control over the degree of methacrylation and thus tune the mechanical 
properties of the resulting hydrogels by modulating the number of crosslinkable side-
groups attached to the polysaccharide chain. To increase the adhesive properties of the 
resulting hydrogels, oxidation of the polysaccharide chain was subsequently implemented 
to form functional aldehyde groups capable of protein interactions through the formation 
of imine bonds on biological tissue surfaces. To test the performance of this 
multifunctional material, burst pressure testing was executed, revealing the relationship 
between the two distinct chemical modifications performed and the mechanical and 
adhesive properties of the resulting sealant. 
 
 In addition, methacrylated alginate was utilized to synthesize therapeutic, drug-
encapsulating hydrogel nanoparticles, which when incorporated within the 
polysaccharide-based surgical sealant allow for local drug release. The ability to control 
drug release at the site of application further broadens the potential uses of this surgical 
sealant patch and will be discussed further within this dissertation. 
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CHAPTER 1: INTRODUCTION 
  
 
1.1. Motivation and Rationale 
Hydrogel materials have long been considered ideal for medical and biological 
applications due to their high water content, and similarity to soft tissues within the 
body.1 For this reason, their use in drug delivery, tissue engineering, and regenerative 
medical applications has increased dramatically.2-18 Within this category fall 
polysaccharide-based hydrogel biomaterials, which consist of a network of long polymer 
chains hydrated in an aqueous solution; these chains are crosslinked to one another 
forming a solid or semi-solid gel. Polysaccharides of various types can be found 
throughout biological systems, and thus can often be exceedingly biocompatible when 
compared with more traditional synthetic polymer materials, often referred to as 
plastics.3, 19 This increase biocompatibility is, in part, due to the biochemical similarity 
between these molecules and those found in the extracellular matrix within many tissues 
and thus make these materials ideal for a vast array of medical applications.19 The basis 
and primary focus of this dissertation is to investigate the chemical functionalization of 
two polysaccharide molecules, hyaluronan and alginate, to promote specific mechanical 
and physical properties necessary for applications in injectable tissue repair, controlled 
therapeutic drug delivery and the adhesive closure of wounds in tissue. 
 
1.1.1. Hydrogel Biomaterials with Tunable Mechanical Properties 
The dawning era of regenerative medicine has introduced a paradigm shift in the 
treatment of diseased, degenerated or damaged biological tissues.17, 20-25 Rather than 
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engineering synthetic replacements for tissues, such as used in joint replacement 
therapies, there is increasing interest in tissue engineering using biomaterial scaffolds that 
encourage and support the innate healing processes of tissue.17, 26 One issue often found 
with biomaterial replacements is the mismatch of mechanical properties to the tissues 
they are designed to replace. For example, a metallic hip replacement far exceeds the 
mechanical properties exhibited by the natural bone making up the hip joint.27-28 Negative 
side effects due to this property mismatch are prevalent, as the excessive mechanical 
properties cause alterations in the dissipation of mechanical stresses.27-30 This, in-turn, 
results in stress concentrations on the metal/bone interfaces, and can result in loosening 
or further tissue damage over time.31 Many replacement biomaterials have limited 
lifespans, and may indeed require repeated replacement/revision procedures throughout 
the life of a patient.29, 31-36 By engineering biomaterial scaffolds with properties more 
closely aligned with innate tissue properties, it is thought that cellular and immune 
responses will be better controlled, and allow for improved healing of damaged tissues.37-
44  It is also hoped that regenerating damaged tissues, rather than replacing them, will 
prevent the need for revision surgeries in the future.45 For example, rather than replacing 
an entire joint, hydrogel scaffolds could be injected into osteochondral defects within the 
joint, temporarily replacing the cartilage surface while simultaneously fostering tissue 
regeneration and healing of the articular surface.21-22, 46-48 This concept and other 
applications which could benefit from injectable hydrogel biomaterials with tunable 
properties will be discussed at length in Chapter 3 of this work. 
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Biocompatability can also be a challenge. When implanted in the body, 
materials can be recognized as foreign objects by the human immune system leading to a 
cascade of immune responses, increased/premature degradation of the material and 
further negative side effects resulting from released degradation by-products.35 Tissue 
engineering using biocompatible polysaccharide-based hydrogel scaffolds with tunable 
mechanical and physical properties has the potential to eliminate many of the concerns 
facing biomaterial tissue replacement, by matching innate tissue properties and allowing 
for cell infiltration and extracellular matrix deposition, with the hydrogel material slowly 
degrading as it is replaced by the individual’s own natural tissue.49 A main priority of the 
work undertaken in this dissertation will be to develop several polysaccharide 
modification chemistries which can be utilized to achieve tunable mechanical properties, 
such as stiffness and elasticity, and ultimately provide a flexible, and biocompatible 
biomaterial hydrogel system for multiple tissue engineering and medical applications.3, 48, 
50 
 
1.1.2. Advancing Surgical Closure Techniques 
There is significant clinical need for improved surgical closure techniques in 
soft tissues. Current methods vary based on tissue type and function, with tissues under 
dynamic stresses such as the lung being more difficult to repair after surgery or injury 
due to the constant inflation and stretching of the surrounding tissues.51-54 The lung also 
poses additional challenges as any residual leakage of air or fluid from the surgical site or 
perforating wound can be trapped within the chest cavity, preventing the lung from 
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inflating.55-58 This life-threatening phenomenon is known as pneumothorax, or lung 
collapse, and requires immediate medical intervention to drain the air or fluid from the 
chest with a chest tube, allowing the lung to re-inflate and the patient to breath.53, 55-61 
Unfortunately, this process does not resolve the underlying tissue damage and often 
leaves patients waiting in the intensive care unit for the tissue to heal on its own. Many 
commonly used wound closure techniques such as staples or sutures often fail to 
completely seal the defect or require secondary surgical removal.51-53, 55-56, 58, 61-64 Tissue 
sealants offer promise for these applications as they have the potential to seal wounds 
completely and can also be engineered to degrade naturally over time, resolving many of 
the issues of traditional closure techniques.65-82 For these reasons, this dissertation will 
feature a thorough investigation into the design, synthesis, and performance of a novel 
polysaccharide based tissue sealant which was designed to be applied to damaged lung or 
soft tissues as a liquid adhesive or a bandage-like patch. 
 
1.1.3. Particle-Mediated Drug Delivery Mechanisms 
Current routes of therapeutic drug administration are primarily limited to broad 
systemic distribution of the medication typically through enteral/enteric administration 
(oral, rectal), or intravenous injection. There are many applications where site-specific or 
cell-specific drug delivery would be more beneficial or prevent systemic side effects, 
such as the case with chemotherapeutics in the treatment of certain cancers.83 
Chemotherapeutics, when delivered systemically, can often induce significant negative 
side effects related to non-specific drug action, which induces apoptosis in rapidly 
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dividing cells.84-86 Although cancer cells are rapidly dividing cells, there are healthy cells 
in the body that divide similarly, such as cells of hair follicles, skin, and the lining of the 
digestive system which exhibit increased cell death during chemotherapy and thus cause 
side effects. There is a dire need for cancer drug delivery systems which allow for 
increased efficacy in cancer cell clearance and yet decreased systemic toxicity.85 Drug 
encapsulating particles (microparticles, nanoparticles, micelles) are of increasing interest 
to biomaterials scientists in hopes that through the inclusion of specific targeting features 
and chemical modifications, we can improve the delivery mechanism and the efficiency 
of drug delivery to the target tissues and cells.7, 83, 87-95 In this dissertation, an 
investigation into the use of doxorubicin encapsulating alginate-based hydrogel particles 
will be performed to assess the benefits of intracellular drug/payload delivery in the 
treatment of human lung cancer.85 
 
1.1.4. Sustainable Biomaterials for Alternative Medicine 
In addition to the primary motivations of this work, a supplementary theme of 
this work is the use of sustainable and naturally-derived materials. Medical waste of 
consumable materials and medical devices should be considered of major environmental 
concern.96-98 Many materials and biomaterials currently utilized for medical applications 
are synthetically-derived, often plastics, who’s synthesis, usage and disposal can impose 
negative environmental effects.97-98 The production of many of these products can 
involve by-products of the fossil fuel industry, or release harmful chemicals into our air, 
ground, and water supplies. These often non-degradable materials will likely remain in 
our landfills for hundreds of years.98 In the work described in this dissertation, two 
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naturally-derived polysaccharides, hyaluronan and alginate, were utilized not only for 
their superior biocompatibility but also in hopes of reducing environmental side effects of 
production and disposal. Hyaluronan is a molecule found ubiquitously in mammals and 
can be bacterially or enzymatically synthesized.99-103 Alginate can be extracted from 
brown algae, which lines many ocean floors and can be sustainably farmed, harvested 
and purified and thus was chosen as the primary material of interest in this dissertation.11, 
104 
 
1.2. Specific Aims of Work 
 
1.2.1. Development of a Novel Polysaccharide Methacrylation Chemistry 
The mechanical properties of biomaterials used in tissue engineering and 
regenerative medical applications are known to influence cell behavior, differentiation 
and tissue regeneration. Thus, one primary aim of this research is to develop a reliable 
means of modulating the mechanical properties of polysaccharide-based hydrogels for 
specific applications. It is hypothesized that through the development of a novel 
anhydrous polysaccharide methacrylation chemistry, it will be possible to control the 
degree of crosslinking occurring between methacrylate groups on adjacent polymer 
chains and ultimately tune the mechanics of the resulting hydrogel. 
 
1.2.2. Design and Synthesis of an Alginate-Based Tissue Sealant 
Surgical sealants have the potential to offer improved performance over 
traditional surgical closure techniques and can be engineered to degrade naturally as 
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tissue regeneration and healing occur. Utilizing methacrylated and oxidized alginates, an 
investigation into the use of a novel polysaccharide-based aldehyde-mediated adhesive 
will be performed to assess its potential use as a pulmonary tissue sealant. It is 
hypothesized that by modulating the degree of alginate oxidation, improved adhesion to 
tissue surfaces will be possible as assessed through burst pressure testing. Furthermore, 
methacrylated and oxidized alginates will be used to fabricate ready-to-use photo-
crosslinkable tissue adhesive patches, which can be applied to tissues like a bandage to 
seal leaks or perforations. 
 
1.2.3. Synthesis of Drug Eluting Alginate-Based Sub-Microparticles 
The ability to control the delivery and release of therapeutic drugs can improve 
treatment efficacy, and reduce side effects imposed by systemic drug administration 
especially in the case of chemotherapies.95, 105-107 Using photo-polymerization techniques 
it is possible to encapsulate chemotherapeutic drug within hydrogel nanoparticles which 
can be readily internalized by cancer cells. For this portion of my work, I hypothesize 
that doxorubicin hydrochloride, a common chemotherapeutic drug, can be encapsulated 
within methacrylated alginate nanoparticles and can subsequently be utilized for 
controlled intracellular drug delivery and the treatment of lung cancer. 
 
1.2.4. Fabrication of a Therapeutic Tissue Sealant Patch 
Medications such as antibiotics or chemotherapeutics are often systemically 
administered after surgeries to prevent infection or eliminate residual cancer cells from 
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resected tumors. The ability to seal a surgical site or wound while simultaneously 
providing controlled local therapeutic drug release at the application site is hypothesized 
to simplify and improve the standard of surgical care while providing benefits to both the 
surgeon and the patient with ease of use and improved health outcomes. In this work, 
doxorubicin encapsulating nanoparticles are incorporated within alginate-based tissue 
sealant patches and utilized to successfully control the local release of the drug to human 
lung cancer cells. 
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CHAPTER 2: SIGNIFICANCE AND BACKGROUND 
 
 
2.1. Introduction 
 Hydrogels are natural or synthetic-based crosslinked polymer networks 
that swell but do not dissolve in aqueous media. Naturally-derived hydrogel biomaterials 
are advantageous compared with their synthetic counterparts due to heightened 
compatibility, degradability, sustainable resources, and intrinsic bioactive qualities. 
Alginate and alginate-based hydrogels are investigated for biomedical applications due to 
their inherent non-toxicity, biocompatibility, and ready availability from sustainable 
sources.1 Derived from brown algae, alginate is desirable not only for those attributes 
already listed, but also for its relatively low cost and the various applications it can be 
used for drug delivery and tissue engineering.2 Alginate will degrade in the body, but 
only hydrolytically. The use of polysaccharides, such as hyaluronan (HA), in biomaterials 
imparts biodegradability through enzymatic activity. HA is a linear, anionic high 
molecular weight polysaccharide found in soft tissue and synovial fluid that swells in the 
presence of water and provides lubrication to articulating surfaces and resistance to 
compressive loads in vivo. A wide variety of cell types express the archetypal HA 
receptor-CD44. These cellular interactions promote wound healing and tissue 
regeneration.20-22 Blends of alginate and other polysaccharides such as HA can form 
interpenetrating network hydrogels, which exhibit long-range elasticity and improved 
dynamic strength. The use of HA can also enhance biodegradation in vivo.3 
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Chemical modification of alginate  and other similar polysaccharides, such as 
hyaluronan, have been studied extensively for their ability to improve upon the physical 
and mechanical properties of crosslinked hydrogels for various applications.4-6 
Methacrylation of alginate imparts a functional group capable of light-activated covalent 
crosslinking by free radical polymerization in the presence of a photoinitiator. This 
review will discuss several relevant applications of methacrylated polysaccharides, and 
will suggest ways in which this functionalization can be improved for usage in injectable 
tissue repair and tissue engineering.  
 
One consideration which will also be discussed is how alginate is inherently 
non-adhesive; however, oxidation of the backbone structure7-8 will elicit functional 
aldehyde groups capable of forming crosslinks with extracellular matrix proteins, such as 
those found on many tissue surfaces.9-10 Aldehyde-mediated protein adhesion has been 
investigated for biomaterial and tissue engineering applications.3, 11-24  
 
In the following sections, I hope to provide background on the use of 
methacrylated and aldehyde-modified materials for use in regenerative medicine, 
providing further justification for the work performed in this dissertation. Subsequently, a 
discussion of additional adhesive tissue sealant materials for biomedical, and pulmonary 
use will be included along with relevant background information on lung biology and 
relevant pulmonary disease. Controlled drug delivery will also be investigated through 
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assessment of the varied biomaterial systems currently in development for controlled 
drug administration, including particle-mediated drug delivery. 
 
2.2. Methacrylated Polysaccharides for Tissue Engineering and Regenerative 
Medicine 
Methacrylation of polysaccharides provides the ability to covalently crosslink 
adjacent polymer chains through free radical polymerization, forming a solid hydrogel 
material that can be used in a vast array of biomedical applications.25 The process 
involves the chemical substitution of free hydroxyl groups with crosslinkable 
methacrylate side-groups.26 Although methacrylation has been used for decades for non-
medical applications, the dawning era of regenerative medicine and the growing interest 
in engineering biological tissues using biomaterial scaffolds has increased the use of this 
modification in the literature dramatically.1-2, 6-7, 9-10, 20, 25-103 The degree of methacrylation 
has been shown to effect the mechanical properties of the resulting hydrogel material, 
suggesting the ability to tailor the material to the designated tissue engineering 
application.39, 104-105 Several chemistries, with varying levels of control over the degree of 
methacrylation, have been developed to methacrylate polysaccharide molecules and yield 
hydrogel materials with a broad range of mechanical properties.27, 39 These methods and 
their associated applications will be discussed in the following sections. 
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2.2.1. Aqueous methacrylation of polysaccharides 
One of the more prevalent methods used to methacrylate polysaccharides is via 
an aqueous, or water-based, reaction.1, 27, 29, 97 Many of these chemistries utilize a simple 
reaction based on a large excess of reactant, such as methacrylic anhydride27 or glycidyl 
methacrylate29 blended into a 1-2 wt% aqueous polysaccharide solution and allowed to 
react overnight.34, 105-109 Although this reaction is reasonably simple to implement, it is 
not without pitfalls. One concern is the formation of methacrylic acid when the large 
excess of methacrylic anhydride blends with aqueous solutions.26, 38, 104-105 If the acidity 
within the reaction vessel increases uncontrolled, polymer degradation will occur, and the 
reaction may cease to continue due to alterations in polysaccharide solubility (i.e. 
precipitation). To reduce the risk of deleterious effects, the pH within the reaction vessel 
must be monitored and frequently adjusted to maintain a slightly basic environment, 
typically using sodium hydroxide.27  
 
Yet another downside to using an aqueous methacrylation chemistry is the lack 
of control afforded over the degree of modification/substitution. In theory, when utilizing 
such a large molar excess of reactants there is no limit to the number of free hydroxyl 
groups that could be modified. High degrees of methacrylation, however, are not 
commonly observed using these reactions due to much of the reactant being spent in the 
aforementioned acid formation.26 Additionally, there are limited means of controlling or 
confirming the level of modification during the reaction process other than guesswork 
and prior experience. This is due to various factors, such as alterations in pH and 
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temperature which will affect the reaction process, and thus batch to batch variation is 
prevalent. Some general control over the degree of methacrylation can be had by limiting 
the reaction time, but better methods of controlling these reactions are required by tissue 
engineers seeking specific mechanical properties in their end-product. 
 
2.2.2. Anhydrous methacrylation of polysaccharides 
Anhydrous methacrylation chemistries, performed in organic solvents, are 
sought to eliminate many of the concerns experienced with aqueous based chemistries. It 
is thought that due to the lack of water in the reaction vessel, acid formation will not 
occur, reducing the quantities of reactants which are required to specific molar ratios. 
These molar ratios can be calculated and stoichiometrically modulated to synthesize 
methacrylated polysaccharides with predetermined levels of modifications. In one study, 
researchers performed both aqueous and anhydrous methacrylation chemistries on 
hyaluronan to elucidate the different levels of control over the degree of hydroxyl 
substitution provided by each reaction.39 In this study, anhydrous reactions are shown to 
allow for improved control over the degree of methacrylation, and thus modulate the 
mechanical properties of the resulting crosslinked hydrogels. This same degree of control 
was not possible to duplicate with methacrylated hyaluronan synthesized via the 
commonly used aqueous methacrylation chemistry.39 Others have also successfully 
implemented anhydrous methacrylation chemistries that allow for superior control over 
the level of polysaccharide functionalization using hyaluronan, alginate and sucrose.26, 63, 
71, 96  
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2.3. Aldehyde-Modified Biomaterials 
The ability of aldehyde groups to crosslink with proteins is well established in 
the literature, and is of increasing interest to those developing materials for bioadhesive 
applications.3, 11-24 Additionally, these functional groups are often utilized as 
crosslinkable side-groups within biomaterial scaffolds for tissue engineering purposes. It 
has also been shown that by opening the uronate residues in alginate, forming aldehyde 
groups, the degradation rates of the resulting hydrogel materials increase by altering the 
molecules susceptibility to hydrolysis.10 Increased degradation rates can be ideal for 
biomedical applications where the implanted materials are meant to be temporary, or in 
tissue engineering applications where the material will be replaced by natural tissue over 
time.9-10, 49 In the following sections, examples of both applications of aldehyde 
modification will be explored. 
 
2.3.1. Aldehyde-Mediated Bioadhesive Materials 
Some of the largest contributions to the field of aldehyde-modified 
polysaccharide research comes from the laboratory of Dr. Eben Alsberg of Case Western 
Reserve University. Their work pioneered the ability to form functional aldehyde groups 
on the alginate molecule through the implementation of an oxidation reaction using 
sodium periodate.9-10, 49, 70, 110 It was also shown that degradation rates can be increased 
by increasing levels of oxidation, resulting in tunable degradation rates.10, 110 
Additionally, the use of aldehyde-modified alginate/poly(ethylene glycol) hydrogels for 
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use in bioadhesive applications was explored and found to be superior to the more 
commonly used fibrin-based sealants when tested using a porcine skin model.9 Others 
have used aldehyde modified alginates as hemostatic clotting agents24 and sealants,18, 97, 
111-113 often blending with gelatin18-19, a protein molecule. 
 
2.3.2. Aldehyde-Mediated Crosslinking for Tissue Engineering 
 Another use of aldehyde functionalization is to provide a crosslinkable site 
between polymer or polysaccharide molecules.12-13, 17, 20 Here, through the incorporation 
of protein molecules, such as gelatin or collagen, within the aldehyde-modified polymer 
solution, a gelation reaction is initiated forming a hydrogel material which can be used 
for tissue engineering and drug delivery applications.12-13, 17, 92 
 
 
2.4. Controlled Drug Release 
Tissue regeneration is a promising field which explores the use of bioactive 
materials and cell signaling molecules to aid the body in the wound healing and 
regenerative processes. Lung tissue engineering and regeneration focus on the repair of 
the lung and pleural tissues after injury or surgery. Therapeutic agents are being 
developed and investigated as potential strategies for tissue regeneration in disease 
models such as chronic obstructive pulmonary disease.114 Modern drug delivery systems 
are designed to maintain the structure and bioactivity of biomolecules and to release 
therapeutics in a controlled and predictable manner. Micro-encapsulation is one of the 
core technologies used in polymer drug delivery systems.115 Microspheres for controlled 
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drug delivery applications are designed to provide uniform dimensions, shield the drug 
from the extracellular environment such as enzymatic attack, and be biocompatible 
and/or bio-resorbable.116 Alginate microspheres have attracted much attention for the 
development of controlled- and sustained-release drug delivery systems for growth 
factors,117 proteins,118 cytokines,58 and cells.5, 119 The fabrication of alginate microspheres 
is favorable for drug delivery due to the relatively mild yet rapid gelation process that 
omits the use of harsh chemicals to ensure stability of encapsulated biomolecules.120-123  
 
2.5. Lung Pathologies and Damage 
The lung is a complex and heterogeneous tissue comprised of airways, bronchi, 
bronchioles, alveoli and a vast network of blood vessels. Injury to the connective tissue 
that lines the lung, the pleura, or to the lung itself can occur from many causes including 
trauma or surgery, as well as lung diseases or cancers.124-125 Bronchopleural fistulas, 
malignant pleural effusions, and traumatic or ventilator-induced pleural injuries are a 
continuing source of morbidity, mortality, and increased health care expenditures in the 
clinic.124-127 All of these conditions can result in lung collapse due to air or fluid filling 
the chest cavity, a serious and life threatening condition that requires immediate 
intervention.128-136 There are currently only limited methods of patching significant 
injuries to stop the air or fluid leak quickly and subsequently allow for healing processes 
to repair the underlying tissue.129-130, 132-133, 135-142 In the following sections, the current 
standards of care for those suffering from these ailments will be discussed in an effort to 
convey the urgent need for improved biomaterial sealant technologies. 
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2.5.1. Lung Collapse 
Pneumothorax, or lung collapse, occurs when a perforation is formed through 
the pleura and into the underlying lung tissue causing air or fluid to leak into the chest 
cavity.129-132, 135-137 If this air or fluid is not released, the lung will be prevented from 
inflating and thus collapse. These injuries are often caused by trauma or surgery but can 
often occur spontaneously in individuals with underlying lung diseases.131, 138, 143 As one 
can imagine, a collapsed lung is immediately life threatening, as it prevents the individual 
from breathing, and requires immediate medical intervention. The insertion of a chest 
tube, through the chest wall, allows for draining of fluids and air from the chest cavity, 
but fails to address the underlying trauma which is causing the leak.134 Unfortunately, 
there are few means of resolving perforations in lung tissue, so many individuals are 
required to remain in the intensive care unit, with a chest tube and vacuum device in 
place, until the wound heals naturally. This can translate to long and repeated hospital 
stays, as well as substantial healthcare expenditures.124 A means of sealing the leaks in 
the lung tissue could reduce hospital stays, by eliminating or reducing the need for a chest 
tube and vacuum system.11, 97, 139, 144-146 
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2.5.2. Pleurodesis 
One technique used in the treatment of alveolar or lung tissue leaks is called 
pleurodesis.138, 140-141, 147-148 This procedure involves the chemical or mechanical irritation 
of tissues surrounding the wound or defect to induce inflammation and swelling, in an 
effort to seal the perforation. Chemical pleurodesis involves the application of an irritant 
material, such as talc139, 141-142, 149, parenteral tetracycline150, doxycycline, and 
bleomycin.149 Although these procedures show some efficacy, several of these antibiotic 
substances can induce allergic reaction or fatal alveolar injury.149 Unfortunately some of 
these treatments are painful due to the irritation142, causing difficulty in breathing, and 
requiring additional applications to maintain the tissue in an inflamed state.149  
 
Mechanical pleurodesis induces inflammation using an abrasive material such as 
a nylon scouring pad (e.g. Marlex mesh scratch pad)..143 These methods have been 
criticized for being too invasive and sometimes do more harm than good due to the side 
effects they can cause.140 Yet, until better alternatives are developed, pleurodesis will 
continue to be offered as the standard of care for those suffering from non-resolving 
pneumothorax and pleural effusions. Thus, our work strives to address the issues of 
current treatments by providing a natural and biocompatible sealant material which could 
be used as an alternative to pleurodesis. 
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2.6. Adhesive Biomaterials for Pulmonary Applications 
Starting in the late 1990’s, fibrin began to be studied as a natural-based polymer 
sealant. Fibrin sealant is a hemostatic consisting of blood coagulation factors fibrinogen, 
factor XIII, thrombin, aprotinin and calcium chloride.151-159 This mixture gives rise to the 
formation of a stable, crosslinked fibrin clot. A reduction in the incidence of pulmonary 
or bronchopleural air leakage of 41% has been associated with the use of fibrin sealant.155 
A 50% reduction of alveolar air leaks after pulmonary resection was achieved with the 
use of an aerosolized fibrin glue (HemaMyst® System) compared to standard stapling 
procedures.160 To improve upon the fibrin sealant, TachoComb® was subsequently 
developed, which combines collagen sheets with a fibrin coating. The limitation with 
these methods is that fibrin is a blood derivative and has the possibility of transmitting 
blood-borne diseases. One report describes the clinical use of non-crosslinked alginate to 
close pleural defects in vivo.161 Non-crosslinked alginate can provoke inflammation, an 
effect not observed with the use of crosslinked alginates.162-163  
While the use of hydrogels as surgical sealants and wound treatments began 
developing in the 1960’s, the use of hydrogels to treat pulmonary and alveolar air leaks 
initiated in the late 1980’s.164 Poly(ethylene glycol) (PEG) is the primary polymer used in 
repairing pulmonary and alveolar air leaks.  
One of the first PEG-based pulmonary seals, FocalSeal®, utilizes a two-solution 
method with a photoinitiator, Eosin-Y, to form a sealant.146, 165-166 Upon exposure of  
blue-green light, the sealant polymerizes to form a crosslinked, flexible hydrogel 
network.166-167 Commercially available Progel® is a two solution sealant consisting of 
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dilute PEG-hydrogen chloride and PEG-sodium phosphate/sodium carbonate solutions, 
which come in a preassembled, dual syringe applicator168. Progel® is the only FDA 
approved pleural sealant, however, it is bioinert and does not aid in therapeutic tissue 
regeneration. Similar to Progel®, PEG and trilysine solutions are mixed upon application 
and crosslink within seconds to form a flexible hydrogel.169 This technology was 
introduced as a surgical sealant in Europe as PleuraSeal®, but never obtained FDA 
approval and later underwent a voluntary recall. These completely synthetic systems do 
not provide a mechanism for therapeutic drug delivery and thus motivate our work to 
develop an alginate based tissue sealant capable local/site-specific drug administration at 
the application site.  
Many of the sealants discussed above contain toxic materials and their 
application consists of multiple steps, making it an involved process for the end user. In 
addition, the above studies lacked the incorporation of therapeutics into the sealant 
material to address underlying diseases, infections, and cancers. The investigative use of 
natural-based hydrogels as therapeutic agents to treat lung leaks and encourage tissue 
regeneration while simultaneously delivering therapeutic molecules has yet to be 
performed and is the focus of the following work. 
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CHAPTER 3: VISIBLE LIGHT CROSSLINKING OF METHACRYLATED 
HYALURONAN HYDROGELS FOR INJECTABLE TISSUE REPAIR 
 
Spencer L. Fenn, Rachael A. Oldinski 
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myself, the first and primary author, including the majority all data analysis, figure 
preparation, and manuscript drafting. The manuscript was co-authored in partnership with 
my supervisor, Rachael Oldinski, who is listed as senior author.  
 
3.1. Abstract   
Tissue engineering hydrogels are primarily cured in situ using ultraviolet (UV) 
radiation which limits the use of hydrogels as drug or cell carriers. Visible green light 
activated crosslinking systems are presented as a safe alternative to UV photocrosslinked 
hydrogels, without compromising material properties such as viscosity and stiffness. The 
objective of this study was to fabricate and characterize photocrosslinked hydrogels with 
well-regulated gelation kinetics and mechanical properties for the repair or replacement 
of soft tissue. An anhydrous methacrylation of hyaluronan (HA) was performed to 
control the degree of modification (DOM) of HA, verified by 1H-NMR spectroscopy. UV 
activated crosslinking was compared to visible green light activated crosslinking. While 
the different photocrosslinking techniques resulted in varied crosslinking times, 
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comparable mechanical properties of UV and green light activated crosslinked hydrogels 
were achieved using each photocrosslinking method by adjusting time of light exposure. 
Methacrylated HA (HA-MA) hydrogels of varying molecular weight, DOM and 
concentration exhibited compressive moduli ranging from 1 kPa to 116 kPa, for UV 
crosslinking, and 3 kPa to 146 kPa, for green light crosslinking. HA-MA molecular 
weight and concentration were found to significantly influence moduli values. HA-MA 
hydrogels did not exhibit any significant cytotoxic affects towards human mesenchymal 
stem cells. Green light activated crosslinking systems are presented as a viable method to 
form natural-based hydrogels in situ. 
 
3.2. Introduction 
The possibility of transplanting stem cells in vivo to treat diseases and injuries, 
in a regenerative way, is becoming a reality. While challenges exist in the successful 
translation of stem cell-based engineered tissues, such as articular cartilage,1-3 stem cell 
transplantation to aid in tissue regeneration may be a viable option. The necessary 
requirements of a tissue engineering construct for a long-term successful regenerative 
approach include physiologically relevant bulk material properties for congruency in 
mechanical loading and energy dissipation, and the ability to biologically guide tissue 
regeneration.4 However, the translation of engineering techniques in situ relies on the 
improvement of hydrogel implantation. One minimally invasive approach is an injectable 
system, in which the hydrogel sets or cures in situ to provide mechanical stability and/or 
serve as a cell and/or drug carrier.5 Hydrogels are used as minimally invasive injectable 
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scaffolds that fill focal articular cartilage lesions.6-8 Injectable hydrogels offer an 
alternative to traditional surgical procedures by developing 3-D scaffolds that promote 
regeneration of cartilage.5, 9-14  
 
Natural, biocompatible materials, such as extracellular matrix (ECM) proteins 
and polysaccharides, have been used to explore the effect of substrate stiffness on 
mesenchymal stem cell (MSC) differentiation and tissue growth.15-16 Hyaluronan (HA) is 
a linear, anionic, high molecular weight polysaccharide found in soft tissue and synovial 
fluid that swells in the presence of water and provides lubrication to articulating surfaces 
and resistance to compressive loads in vivo. A wide variety of cell types express the 
archetypal HA receptor CD-44; CD-44-HA interactions are essential for maintaining 
normal cartilage homeostasis. These cellular interactions are advantageous for promoting 
wound healing and tissue regeneration.17-19 Integrin-mediated cell-material interactions 
and substrate stiffness of hydrogels impact MSC differentiation.20-22 The focus of the 
current study was to mechanically analyze methacrylated HA (HA-MA) hydrogels 
undergoing either ultraviolet (UV) or visible green light crosslinking for the purpose of 
achieving a wide range of elastic moduli values for various tissue engineering 
applications. 
 
Through careful selection of both the DOM and molecular weight of HA, a 
range of mechanical properties can be achieved and optimized for the regeneration of 
desired tissues. Methacrylation of polysaccharides, including HA, have been reported in 
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the literature.23-25 However, most studies have not examined non-aqueous methacrylation 
reactions, which allow for more precise control over stoichiometric ratios and the DOM, 
nor do previous studies report on variance of photocrosslinking methods via different 
light sources and photoinitiator systems. Accurate control of the DOM allows for tunable 
crosslink densities and mechanical properties, with future direction focused on injectable 
tissue repair. This work aimed to determine how the source of light-activated covalent 
crosslinking of HA-based hydrogels affects rheological and mechanical properties for the 
development of an injectable hydrogel for tissue engineering applications. The goal of 
this study was to design and fabricate green light activated crosslinking systems are 
presented as a safe alternative to UV photocrosslinked hydrogels, without compromising 
material properties such as viscosity and stiffness. 
 
3.3. Materials & Methods 
3.3.1. Synthesis of Methacrylated Hyaluronan (HA-MA) 
Sodium HA (Lifecore Biomedical) lyophilized powders of two different 
molecular weights (Mw = 100 and 700 kDa) were rendered soluble in anhydrous 
dimethyl sulfoxide (DMSO, 99% anhydrous, Sigma Aldrich) through an ion exchange 
with hexadecyltrimethylammonium bromide salt (CTAB, Sigma Aldrich). Ion exchange 
resin (Dowex 50WX8-400) was loaded with CTA+ ions by submersion in a 1-2% (w/v) 
CTAB ethanol:water solution (1:1 ratio), then mixed with 1% (w/v) HA in deionized 
water for 24 hours at 40°C. The polymer solution was filtered to remove ion exchange 
resin, frozen and lyophilized (See Appendix II for detailed protocol). A 1% (w/v) HA-
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CTA/DMSO solution was reacted with methacrylic anhydride (MA, Sigma Aldrich) in 
the presence of a catalyst, 4-(dimethylamino)pyridine (DMAP, Sigma Aldrich), for 24 
hours at room temperature. The amount of MA was adjusted to achieve varying DOMs 
based on molar ratios of the hydroxyl groups (modification sites) per HA repeat unit to 
MA. The amounts of MA utilized in this study were 1x, 1.5x, and 2x the molar quantity 
of hydroxyl groups (See Appendix IV for calculations performed). The resulting solution 
was hydrolyzed through extensive dialysis and periodic adjustment to pH 8 with 5N 
sodium hydroxide. The DOM, or ratio of methacrylate groups per repeat unit of HA-MA, 
was determined using 1H-NMR spectroscopy (Bruker AVANCE III 500 MHz high-field 
NMR spectrometer). A 1% (w/v) polymer in deuterium oxide solution was analyzed at 
room temperature, spinning at 20 Hz for 16 scans. The DOM was calculated by taking 
the ratio of the relative integrations of the methacrylate peaks (6.1, 5.6, and 1.8 ppm), and 
HA methyl protons (1.9 ppm).23, 26 
 
3.3.2. Green Light Crosslinking  
HA-MA solutions of different concentrations (2, 3 or 4% (w/v)) and having 
various molecular weights and DOMs were prepared for visible green light crosslinking. 
To analyze different combinations of crosslinking reactants, aqueous solutions of the 
following concentrations were prepared (See Appendix VII for detailed protocol): 1 mM 
Eosin Y (EY, photosensitizer), 125 mM triethanolamine (TEOA, initiator), 20 mM 1-
vinyl-2-pyrrolidinone (VP, catalyst).23, 27-28 To determine the most effective photoinitiator 
system for green light activation, an absorption assay was conducted on solutions 
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containing EY, EY supplemented with TEOA, EY supplemented with VP, and EY 
supplemented with TEOA and VP. The solution with the highest absorbance at 530 nm 
was chosen as the photoinitiator system for subsequent tests. 
 
3.3.3. Photo-Rheometry 
Viscosity and shear stress, as functions of shear rate, were evaluated on the 
reaction solutions for the preparation of photocrosslinked HA-MA hydrogel. All 
measurements were carried out on a rheometer (AR2000, TA Instruments) equipped with 
a Peltier plate maintained at 25°C and a 40 mm diameter 1°59'47" steel cone geometry. 
100 kDa and 700 kDa HA-MA with varying DOMs were mixed with photoinitiator 
solutions for either UV or green light-activated chemistries to form 3% (w/v) 
concentrated hydrogel pre-curser solutions. To form solutions for UV-activated 
photocrosslinking, a 0.05% (w/v) Irgacure D-2959 (Ciba) solution in phosphate buffered 
saline (PBS) was prepared (See Appendix VI for detailed protocol).25, 29-34 To form 
solutions for green light crosslinking, a 1 mM EY, 125 mM TEOA, 20 mM VP solution 
was prepared (See Appendix VII for detailed protocol).23, 27-28 Aliquots of 500 µL were 
placed within a 27 µm gap between the Peltier plate and cone geometry. Viscosity (Pa*s) 
and shear stress (Pa) of the polymer solutions were determined at varied shear rates, 1-50 
(1/s), at 1% radial strain over 2 minutes (n = 3) and analyzed using analytical software 
(TA Data Analysis). 
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The gelation of HA-MA hydrogels was examined immediately following shear 
sweep experiments. Oscillatory time sweeps were conducted at 10% radial strain and 1 
Hz during exposure to UV (320 - 390 nm, Uvitron Intelliray 400) or green light (530 nm, 
custom 20 LED array, 14 kmCd, Victory Rush Electronics) (n = 3). Data collection was 
initiated upon the start of light exposure. Shear loss (G') and storage (G") moduli were 
recorded; tan delta (ratio of G" to G') was analyzed using analytical software (TA Data 
Analysis). HA-MA gelation initiation was identified at the inflection point in the tan delta 
curve and the terminal gelation time was approximated to occur as G’ plateaus. 
 
3.3.4. Unconfined Compression Testing 
Uniaxial unconfined compressive testing was performed on 2, 3 and 4% (w/v) 
HA-MA hydrogels crosslinked using either UV or green light to elucidate any differences 
in mechanical properties between the two crosslinking systems (n = 4). The effects of 
molecular weight and DOM were also investigated. Hydrogel pre-curser solutions were 
placed in a custom mold consisting of glass microscope slides and 1.6 mm thick Teflon® 
spacers. Molds were exposed to either UV light for 10 minutes or green light for 20 
minutes at room temperature; photocrosslinking times were chosen to ensure that the 
hydrogels were terminally crosslinked using each method. Crosslinked samples were 
equilibrated in PBS, pH 7.4, for 24 hours at room temperature (n = 5) prior to testing. 
Specimens 6 mm in diameter and 1.6 mm in height were stamped using a biopsy punch. 
Compression testing was performed on a rheometer, equipped with a normal force 
transducer using an 8 mm parallel plate geometry and an opposing Peltier plate at 25°C. 
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A 10% uniaxial compressive strain was applied at a rate of 10 µm/s. Force (N) and 
changes in gap height (µm) were obtained using analytical software (TA Universal 
Analysis) and were subsequently used to calculate elastic strain (ε, %) and stress (σ, kPa). 
The elastic modulus (E) was calculated as the slope of a linear fit between 4 and 10% 
compressive strain within the linear-elastic region.  
 
3.3.5. Cytotoxicity Assay 
The cytotoxicity of photocrosslinked hydrogels to primary bone-marrow derived 
human MSCs was assessed spectrophotometrically as a function of mitochondrial activity 
in living cells using an MTT based assay. Primary bone-marrow derived human MSCs 
(passage 7) were seeded in treated 48-well tissue culture polystyrene plates at a density of 
20,000 cells/well in 100 µL/well of standard MSC growth medium (alpha minimum 
essential medium, 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL 
streptomycin) and allowed to adhere for 24 hours. MSCs were incubated in the presence 
of various photocrosslinked HA-MA hydrogels (n = 4) at 37°C and 5% CO2. Hydrogels 
were fabricated using 100 kDa or 700 kDa HA-MA, 2 or 4% (w/v) polymer 
concentrations, and high DOMs. Hydrogels were terminally photocrosslinked prior to cell 
culture during exposure to either UV for 10 minutes or green light for 20 minutes. 
Hydrogel specimens were 6 mm wide and 2 mm tall. After 24 hours of incubation, 
medium was removed and cells were rinsed two times in sterile PBS. Mitochondrial 
activity was analyzed using an MTT-based In Vitro Toxicology Assay Kit (Sigma) 
following the manufacturer’s protocol with a plate reader (H1 Synergy, BioTek). Briefly, 
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mitochondrial dehydrogenases in viable cells cleave the tetrazolium ring in MTT, 
yielding formazan crystals which can be dissolved and measured spectrophotometrically. 
Absorbance values were recorded at 570 nm with background absorbance at 690 nm 
deducted. Average absorbance values for the experimental samples were compared to 
positive control values recorded for wells containing media and cells alone (See 
Appendix VIII for detailed protocol).35  
 
3.3.6. Statistical Analysis 
All experiments were performed in triplicate with results reported as mean ± 
standard deviation. Statistical analysis was performed with a GLM procedure using 
Statistical Analysis System software. A fixed effect tri-factorial (concentration, molecular 
weight, and crosslinking method) model was generated to study the contribution of each 
factor to HA-MA hydrogels with a range of compressive elastic moduli. The multiple 
comparisons were performed based on a two-way ANOVA of individual and interaction 
effects of the three factors. For analyzing cytotoxicity, similar GLM procedures were 
preformed to obtain one-way ANOVA results. A p < 0.05 was considered significantly 
different. 
 
3.4. Results  
3.4.1. HA-MA Synthesis and Characterization 
An anhydrous methacrylation of HA resulted in a functionalized polymer with a 
controllable DOM. Relative integrations of methacrylate groups, as identified in the 
 54 
 
chemical structure and 1H-NMR spectra (Figure 1), resulted in varied DOM for both 100 
kDa and 700 kDa HA.  The various DOMs achieved were 71% (low), 81% (medium), 
and 90% (high) for 100 kDa HA-MA, and 43% (low), 54% (medium), and 68% (high) 
for 700 kDa HA-MA. Higher DOMs were achieved for the lower molecular weight HA. 
The CTA+ groups were removed and replaced with Na+ as confirmed through HA-MA 
dissolution in aqueous based solutions (i.e., DI water and PBS) and 1H-NMR spectra. 
 
Figure 1: Chemical structure schematic of methacrylated hyaluronan (HA-MA) repeat unit (top) and 
1H-NMR spectra of various HA-MA polymers. Varying degrees of modification (DOM) were 
achieved through controlled stoichiometric ratios of HA and methacrylic anhydride. The DOM was 
calculated by taking the ratio of relative integrations of methacrylate peaks (6.1, 5.6, or 1.8 ppm), 
and HA methyl protons (1.9 ppm). Methacrylate protons at a, b, c and HA’s methyl proton at d are 
identified in the chemical structure and associated 1H-NMR spectra peaks. 
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3.4.2. Green Light Crosslinking 
The photoinitiator system for green light crosslinking and the effects of 
including an initiator and a catalyst were investigated for optimum absorbance upon light 
exposure. An absorption assay, performed on a microplate reader, was utilized to 
quantify light absorbance of various photoinitiator solutions (Figure 2). The 
photoinitiator solution comprising 1 mM EY, 125 mM TEOA, 20 mM VP exhibited the 
highest absorbance at 530 nm and was thus used for green light crosslinked HA-MA 
hydrogels.  
 
 
Figure 2: Visible light absorption of green light-activated crosslinking reactants was quantitatively 
determined using an aqueous-based absorbance assay. Reactants were placed in DI water at the 
following concentrations: 1 mM Eosin Y (EY, photosensitizer), 125 mM triethanolamine (TEOA, 
initiator), 20 mM 1-vinyl-2-pyrrolidinone (VP, catalyst). Using a microplate reader, absorbance at 
530 nm was recorded for solutions containing EY (dashed and dotted line), EY supplemented with 
TEOA (dashed line), EY supplemented with VP (dotted line), and EY supplemented with TEOA and 
VP (solid line). 
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3.4.3. Shear Strain Sweep Measurements 
Viscosity and shear rate values for various HA-MA hydrogel pre-curser 
solutions varied; the effects of shear rate on viscosity and shear stress values of 3% HA 
and HA-MA solutions are shown in Figure 3. Viscosity values for 100 kDa HA-based 
solutions were lower compared the 700 kDa HA-based solutions. Solution viscosities 
decreased exponentially with increasing shear for all solutions tested (Figure 3A,B). The 
HA-MA solutions exhibited lower viscosity values compared to the HA controls. At a 
shear rate of 10 (1/s) and 1% displacements, all three of the 100 kDa HA-MA solutions 
(DOM = low, medium, high) exhibited an 11-fold decrease in viscosity values compared 
to the non-modified HA control (Figure 3A), while the 700 kDa HA-MA solutions 
exhibited 3, 9, and 16-fold decreases in viscosity values for low, medium, and high DOM 
compared to the HA control (Figure 3B). For the experimental groups, viscosity 
decreased with increasing DOM.  
 
Analogous to the viscosity results, the 700 kDa HA-based solutions exhibited 
higher shear stress values compared to the 100 kDa HA-based solutions (Figure 3C,D). 
The 100 kDa HA-based solutions displayed a linear increase in shear stress with 
increasing shear rate (Figure 3C); however, shear stress increased exponentially with 
increasing shear rate for all 700 kDa HA-based solutions tested (Figure 3D).  
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Figure 3: Viscosity and shear stress as a function of shear rate are presented for HA-MA hydrogel 
pre-curser solutions. 100 kDa or 700 kDa HA-MA, with varying DOMs, were mixed with photo-
initiators in DI water; 3% (w/v) HA-MA solutions were tested at 1% radial strain and 10 Hz. 
Viscosity values are shown for (A) 100 kDa and (B) 700 kDa HA-MA solutions (n = 3); shear stress 
values are shown for (C) 100 kDa and (D) 700 kDa HA-MA solutions (n = 3). Legend: HA control – 
solid triangle; HA-MA low DOM – white circles; HA-MA med DOM – grey circles; HA-MA high 
DOM – black circles. 
 
3.4.4. Gelation Behavior of HA-MA  
HA-MA solutions of different concentrations, in the presence of photoinitiators, 
were successfully crosslinked and formed into hydrogels upon exposure to either UV or 
green light. The gelation times of HA-MA solutions activated by either UV or green light 
were approximated from oscillatory time sweeps. Tan delta was plotted versus time (Figure 
4A,C) and the onset of gelation was determined to be the point of inflection where the 
slope of the tan delta curve became negative. Due to this clear inflection, the tan delta is a 
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clearer indication of the initiation of gelation, whereas the G’ is more indicative of terminal 
crosslinking as it plateaus (Figure 4B,D).  
 
Due to air exposure and warming to 37°C, dehydration was observed in polymer 
solutions after 800 seconds causing high variability and unreliable data (data not shown) 
and thus approximations for terminal gelation times for both crosslinking systems were 
made as follows. For the UV crosslinked hydrogels, G’ appears to plateau at approximately 
600 seconds. For green light crosslinked gels, tan delta exhibits delayed gelation initiation 
as compared to UV and G’ fails to plateau by 800 seconds indicating that gelation had not 
terminated by this point. The extended gelation time for green light crosslinked gels can be 
attributed to the lower intensity of the LEDs used as compared to the high intensity lamp 
used to produce UV light. Terminal crosslinking densities were approximated to be 
achieved after 10 and 20 minutes for UV and green light crosslinking, respectively. Thus, 
these exposure times were used to form hydrogels for mechanical testing. 
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Figure 4: The effect of photocrosslinking light source on gelation kinetics and hydrogel formation 
was analyzed using 3% (w/v) solutions of HA-MA with high degrees of modification (DOMs). 
Oscillatory time sweep experiments were conducted at 10% radial strain and 1 Hz. Tan delta values 
for (A) 100 kDa and (C) 700 kDa are plotted alongside corresponding storage (G’) and loss (G”) 
shear moduli values for (B) 100 kDa and (D) 700 kDa. Solutions were exposed to either UV (320–390 
nm, Uvitron Intelliray 400) or green light (530 nm, custom 20 LED array, 14 kmCd, Victory Rush 
Electronics) to activate photocrosslinking (n = 3). 
 
3.4.5. Unconfined Compression Testing 
Uniaxial unconfined compression tests were conducted on UV and green light 
crosslinked HA-MA hydrogels. The UV crosslinked hydrogels exhibited elastic moduli 
values ranging from 1 kPa to 116 kPa (Figure 5A), while the green light crosslinked 
hydrogels exhibited elastic moduli values ranging from 3 kPa to 146 kPa (Figure 5B). 
The high molecular weight hydrogels (700 kDa HA) exhibited higher elastic moduli 
values compared to the low molecular weight hydrogels (100 kDa HA) for both 
photocrosslinking systems. The elastic moduli of photocrosslinked HA-MA hydrogels 
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demonstrated significant correlations with molecular weight, DOM, and polymer 
concentration after performing a factorial analysis of the compressive data (p ≤ 0.003).    
 
 
Figure 5: Uni-axial unconfined compression experiments were conducted on photocrosslinked HA-
MA hydrogels. The effect of polymer concentration (w/v), molecular weight, degree of modification 
(DOM), and light source were evaluated. (A) UV (10 minute terminal crosslinking time) and (B) 
green light (20 minute terminal crosslinking time) crosslinked HA-MA hydrogels consisted of low, 
medium, and or DOM and HA-MA concentrations of 2, 3 or 4% (w/v). Results are shown as average 
± standard deviation, n = 5. 
 
 
3.4.6. Cytotoxicity Assay 
Primary human MSCs were cultured with photocrosslinked HA-MA hydrogels 
for 24 hours in standard MSC culture medium. Hydrogels varied by crosslinking method, 
molecular weight, and HA-MA concentration. Measurements were made using a MTT 
assay to quantify mitochondrial activity and HA-MA experimental hydrogel groups were 
compared to a positive control consisting of medium and cells alone (see Figure 6). 
Elevated absorbance corresponds to increased mitochondrial activity and viability; the 
 61 
 
HA-MA hydrogel scaffolds were found not to be cytotoxic as compared to a positive 
control. Increased cell mitochondrial activity was found in all four of the tested 
experimental groups.  
 
 
Figure 6: The cytotoxicity of photocrosslinked HA-MA hydrogels was evaluated after 24 hours of 
culture with primary human MSCs in standard MSC culture medium. Using a MTT assay to 
quantify mitochondrial activity, average absorbance values for each hydrogel experimental group 
were recorded and compared to control wells containing medium and MSCs alone. HA-MA with a 
high DOM was used. Hydrogels varied by crosslinking method (UV or green light), molecular weight 
(100 kDa or 700 kDa), and HA-MA concentration (2 or 4%, w/v). Elevated absorbance values 
indicate increased mitochondrial activity in all experimental groups. 
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3.5. Discussion 
The implementation of injectable materials curable in situ relies on hydrogel 
systems that are tunable and easily manipulated. Photocrosslinking systems require light 
exposure of a polymer solution to induce covalent crosslinking between neighboring 
chains. Depending on the light source and the polymer/solution conditions, the hydrogel 
network can vary dramatically resulting in different mechanical properties. In addition to 
controlling the mechanical properties of the hydrogel, ease of use is an essential 
requirement of the end user, with low viscosities and short gelation times preferred. 
Furthermore, careful selection of the light source may eliminate unwanted side effects, 
such as cell death, and drug and material degradation. Injectable material systems can be 
accompanied by a laparoscopic lens and LEDs to photocrosslink materials in situ.5 
 
The methacrylation chemistry utilized in this study allowed for the controlled 
modification of HA and thus a broad range of DOMs was achieved. The 100 kDa HA 
was found to react more efficiently and increased DOMs were achieved compared to the 
700 kDa HA-MA hydrogels under the same reaction and crosslinking conditions. This 
increase in reaction efficiency may be attributed to decreased solution viscosities in the 
reaction vessel, as a result of fewer intramolecular and intermolecular interaction between 
shorter polymer chains. Furthermore, shear strain sweeps revealed that a higher DOM 
resulted in decreased viscosity (Figure 3A). This is attributed to degradation of the 
polymer chains during the ion exchange process and the use of sodium hydroxide. 
Decreased viscosity may also be attributed to reduced physical interactions between 
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adjacent HA-MA chains as a result of the conversion of hydroxyl groups to methacrylate 
groups. In addition, the higher molecular weight HA-based solutions, including the HA-
MA experimental groups, exhibited higher viscosities compared to the lower molecular 
weight polymer. The trends that were seen in the viscosity data were also revealed in the 
shear stress data, which was expected since the two values are mathematically related. 
Indeed the viscosity and shear stress values complement the mechanical data collected 
during compression testing.  
 
Photo-rheometry experiments revealed that the reaction kinetics for the two 
crosslinking methods are different. The initiation of gelation, or the gel point, was 
identified as the inflection point of the tan delta curve, and this value varied for each of 
the polymer formulations tested (Figure 4). As shown in Figure 4, the initiation of 
gelation for UV and green light crosslinking were different and so were the times reached 
as tan delta approached zero, which indicates the rate of increase of G’, the storage 
modulus, compared to G”, the loss modulus. For both molecular weights investigated, the 
green light crosslinked hydrogels took approximately twice as long as the UV crosslinked 
hydrogels for the tan delta to approach zero, indicating that green light required twice as 
much time to crosslink and for the storage modulus to equilibrate (i.e., to cease 
increasing). Indeed, the hydrogels are considered to be terminally crosslinked when the 
storage modulus, G’, no longer increases with light exposure time.  The UV crosslinked 
hydrogels demonstrated terminal crosslinking at approximately 10 minutes, however the 
green light crosslinked hydrogels exhibited increasing G’ values after 10 minutes. 
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Limitations of the material and the testing equipment resulted in fluctuating data (noise) 
after 13 minutes. Thus, combing the photo-rheometry, it was decided to use 10 minutes 
for UV crosslinked hydrogels and 20 minutes for the green light crosslinked hydrogels. 
Gelation times are dependent on light intensity; therefore, these times may be adjusted 
depending on light source and distance. Indeed, future work will also focus on optimizing 
the reaction kinetics of the visible light crosslinking system through chemical 
modifications.  
 
The unconfined compressive elastic moduli results of the HA-MA hydrogels 
demonstrated that the method of photocrosslinking did not significantly impact 
mechanical properties, as long as the terminal degree of crosslinking was reached, which 
was approximated from photo-rheometry data. As shown in the literature, the molecular 
weight and solution concentration had more of an influence on the compressive stiffness; 
increasing elastic moduli were achieved with higher concentrations and higher molecular 
weights of HA.11  
 
Indeed, the results show that the two photocrosslinking methods result in 
hydrogels with comparable mechanical properties; thus, visible green light it is a safe 
alternative to UV without comprising material performance. It is hypothesized that the 
green light crosslinking system may be better suited for curing in situ. All of the hydrogel 
formulations tested for toxicity to primary human MSCs displayed enhanced 
mitochondrial activity, further demonstrating terminal crosslinking and the lack of 
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toxicity due to residual photoinitiators and or methacrylation byproducts. While the 
crosslinking time for the HA-MA hydrogels exposed to green light is rather long at 20 
minutes, the elastic moduli achieved are relatively high for low concentration systems.36 
The use of high molecular weight HA decreases crosslinking efficiency, but results in a 
stiffer and tougher network hydrogel. 
 
Hydrogel crosslink density has also been shown to influence hypertrophic 
differentiation of MSCs.37 It is desirable to achieve moderate stiffness values while 
maintaining moderate to low crosslink densities. With the use of a relatively low 
viscosity HA-MA solution, the material can be injected and cured in situ to form a 
hydrogel using a non-invasive laparoscopic procedure. The use of visible light will 
enable a safer approach for the use of injectable hyaluronan hydrogel systems. 
 
3.6. Conclusions  
In this study, an anhydrous HA methacrylation was performed to control the 
DOM of HA, thus controlling the mechanical properties of photocrosslinked HA-MA 
hydrogels. UV and green light activated crosslinking systems resulted in varied gelation 
reaction kinetics; however, terminally crosslinked hydrogels exhibited comparable 
mechanical properties after exposure to UV or green light.  The terminal crosslinking 
densities were achieved after 10 and 20 minutes for UV and green light crosslinking, 
respectively. Thus, these exposure times were used to form hydrogels for mechanical 
testing. The hydrogel elastic moduli demonstrated significant correlations with molecular 
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weight, DOM, and polymer concentration. In addition to presenting green light as a 
viable crosslinking methodology for natural-based materials, the compressive elastic 
moduli of visible light crosslinked HA-MA hydrogels reported here expand upon values 
in the literature, providing a more mimetic moduli range for biomedical applications.  
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CHAPTER 4: MECHANICAL PROPERTIES AND FAILURE ANALYSIS OF 
VISIBLE LIGHT CROSSLINKED ALGINATE-BASED TISSUE SEALANTS 
 
Patrick N. Charron*, Spencer L. Fenn*, Rachael A. Oldinski 
*Indicates Dual First-Authorship 
 
Contributions 
The following manuscript was drafted jointly, between two co-first-authors, 
myself and Patrick N. Charron M.S.. All experimental work disclosed in this chapter was 
shared between the two first authors. I was personally responsible for the methacrylation 
and photo-polymerization chemistries & analysis, protocol development, figure 
preparation, and manuscript revisions. Patrick Charron was responsible for burst pressure 
testing and rheometry. Third author, Alex Poniz, was responsible for burst pressure 
device fabrication. Senior author Rachael Oldinski was involved in all stages of 
manuscript development and editing. 
 
4.1. Abstract 
Engineered surgical sealants and tissue adhesives are becoming more prevalent 
in surgical suites as current medical and robotic technologies improve, simplifying the 
procedures of complex internal surgeries. These tissue sealants serve as an alternative 
method for rejoining and sealing tissues over sutures and staples. This study investigated 
the potential for chemically-modified alginate hydrogels to serve as effective surgical 
tissue sealants. Burst pressure properties and adhesion characteristics were used to 
examine the efficacy of an alginate-based tissue sealant. Burst pressure experiments were 
conducted on a custom-fabricated burst pressure device using constant air flow; pressure-
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time plots quantified burst pressure and total volume at failure. Experimental observation 
and digital videography verified cohesive and adhesive failure of experimental and 
control sealants. In summary, visible light crosslinked alginate tissue sealants formed 
effective seals and maintained pressures up to 50 mm Hg. 
 
4.2. Introduction 
For several decades, breakthroughs in medical technologies have improved 
patient care while also reducing the invasiveness and recovery time for many procedures. 
In particular, advances in laparoscopic surgery have allowed for internal procedures to be 
performed through small incisions, decreasing the need for many open-body operations.1-
3 In these minimally-invasive surgeries, common approaches to rejoin or seal tissues, 
such as sutures or staples, can be difficult to implement, may cause further damage to 
tissue, and often fail to completely seal tissue resulting in the leakage of bodily fluids or 
air.1, 4 An alternative method for providing a simple, immediate seal for wound closure is 
the use of new engineered tissue sealants, which are applied as a liquid and activated on 
demand to adhere, cure, and bond in situ. 1, 5 
 
Tissue sealants are commonly formed using natural or synthetic polymers, or 
both. Synthetic sealants, capable of higher mechanical strengths and tissue-bonding 
properties, are potentially cytotoxic, may cause chronic inflammation, and exhibit low 
adherence to wet tissues.4 Natural based sealants are advantageous compared to their 
synthetic counterparts due to heightened biocompatibility, degradability, sustainable 
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derivation, and intrinsic bioactive qualities.6-11 The abundant resource, propensity for 
chemical modification, and enhanced biocompatibility, degradability, and non-toxicity 
make alginate and alginate-based hydrogels prime candidates for tissue sealant 
applications.7, 12-13 Alginate, derived from brown algae, is desirable not only for those 
attributes already listed, but also for its relatively low cost and historical use in drug 
delivery and tissue engineering.7, 13 While alginate hydrogels can form films in situ via 
calcium crosslinking, these materials are relatively weak (i.e., low elasticity, toughness), 
and exhibit relatively quick degradation times. 
 
Chemical modification of alginate and similar polysaccharides allows for 
designed physical and mechanical properties of engineered alginate hydrogels through 
controlled covalent crosslinking, thus addressing limitations associated with ionically 
crosslinked alginate hydrogels.7, 11, 14-15 The methacrylation of alginate imparts an 
acrylate functional group capable of covalent crosslinking with itself by free radical 
polymerization in the presence of a photoinitiator.7, 15-16 While tradition photo-
crosslinking mechanisms often employ ultraviolet (UV) light activation, UV exposure is 
cytotoxic and degrades biological molecules (e.g., drugs).17-22 As a safer alternative, 
methacrylated alginate (Alg-MA) also covalently crosslinks upon exposure to visible 
light in the presence of the photosensitizer, Eosin Y.12, 16, 23-24  Furthermore, while 
alginate is inherently non-adhesive, oxidation of the backbone structure 25-26 will elicit 
functional aldehyde groups capable of forming covalent bonds with amine groups present 
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on tissue (i.e., imine bond formation) like those found in extracellular matrix (ECM) 
proteins.27-29   
 
Burst pressure testing is a useful means of analysis for tissue sealants, as it 
allows for quantification of the sealant mechanical strength under characteristic loading 
conditions. Burst pressures were collected following a modified standard (ASTM F2392), 
which quantifies not only maximum burst pressures, but also the mode of failure 
(cohesive, i.e., material failure, versus adhesive failure) for the various hydrogel 
compositions.30 In addition, a video recording system may be employed to further 
characterize the mode of sealant failure. Burst pressure and failure data analysis provides 
a direct comparison of tissue sealant mechanical behavior and also enables indirect 
insight into the effects of material integrity and tissue adhesion; burst pressure 
experiments and rheological characterization of novel hydrogels provides insight into 
material structure-function relationships, in order to optimize material properties for 
biomedical applications. 
 
This paper presents the fabrication and characterization of Alg-MA-Ox tissue 
sealants, specifically for use in sealing damaged lung tissue. Our investigation seeks to 
quantitatively assess the effect of modulating the degree of methacrylation and oxidation 
on adhesion and burst pressure properties. The novelty of our approach lies in the 
implementation of both methacrylation and oxidation chemistries to vary mechanics and 
adhesion, as well as our use of visible light crosslinking to reduce the cytotoxic effects 
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observed with UV-cured sealants. We hypothesized that an Alg-MA-Ox hydrogel will 
form an effective seal over an air leak upon exposure to visible light. Furthermore, we 
hypothesized that the Alg-MA-Ox hydrogels would adhere to an ECM substrate and 
exhibit high burst pressures in a physiologically-relevant environment. To test these 
hypotheses, a custom burst pressure device was designed, fabricated, and implemented 
for the quantitative and repeatable mechanical analysis of visible-light crosslinked 
alginate-based hydrogel tissue sealants.  
 
4.3. Materials and Methods 
4.3.1. Synthesis of methacrylated alginate (Alg-MA)  
Alg-MA was synthesized using an aqueous-based reaction. One percent (w/v) 
sodium alginate (Manugel, Mw ≈ 200 kDa, FMC Biopolymer) solution, in deionized (DI) 
water, was reacted with a 20-molar excess of methacrylic anhydride (Sigma Aldrich) for 
12 hours.12, 16, 31-33 The reaction product was treated with sodium hydroxide and dialyzed 
in DI water for 3 days (See Appendix I for detailed protocol). The degree of 
methacrylation (DOM), or ratio of methacrylate groups per repeat unit of alginate, was 
determined using 1H-NMR spectroscopy (Bruker AVANCE III 500 MHz high-field 
NMR spectrometer). Briefly, Alg-MA was dissolved in deuterium oxide (D2O) at 1% 
(w/v) solution and was analyzed at room temperature, spinning at 20 Hz for 16 scans. 
The DOM was determined by calculating ratios of methylene (6.1, 5.6 ppm) and alginate 
methyl (1.9 ppm) peak integrations.16 Alg-MA material with a single DOM was used for 
subsequent rheological and mechanical analysis, and modification via oxidation.  
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4.3.2. Synthesis of oxidized methacrylated alginate (Alg-MA-Ox) 
Alg-MA was reacted with sodium periodate (Sigma) to open the uronate 
residues, which form the alginate backbone, creating an aldehyde group.8, 27 One percent 
(w/v) alginate solutions were prepared by dissolving sodium alginate or Alg-MA in DI 
water. Different volumes of a 3% (w/v) sodium periodate solution were added to the 
alginate solutions and reacted in the dark for 24 hours at room temperature to achieve 
distinctly different degrees of oxidation (DOO).  The Alg-MA and sodium periodate 
solutions were mixed together and stirred for 24 hours in a dark environment at room 
temperature. The product, Alg-MA-Ox, was purified by dialysis in DI water (MWCO 6 
kDa, Thermo-Fisher) for three days and lyophilized (See Appendix IX for detailed 
protocol). Theoretical DOO values were 10, 30 and 50% modification; experimental 
values were determined by comparing the ratio of alginate methyl protons (5.5 and 5.0 
ppm), to the newly formed methyl protons (5.0 ppm).27 In addition, the DOM was 
reassessed after the oxidation reaction (see methods above). 
 
4.3.3. Polymer characterization and visible light crosslinking  
Viscosity and shear stress, as functions of shear rate, were evaluated on Alg-MA 
and Alg-MA-Ox hydrogel sealant precursor solutions (i.e., prior to photo-crosslinking). 
All measurements were carried out on a rheometer (AR2000, TA Instruments) equipped 
with a Peltier plate maintained at 25°C, using a 40 mm diameter 1°59′47″ hard anodized 
aluminum cone geometry. Alginate and chemically-modified alginate powders were 
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added to DI water to form 3% (w/v) alginate solutions of the following compositions: 
alginate controls, Alg-MA (DOM = 77), Alg-MA-Ox (DOO = 10, 30, 50), and 50:50 
polymer blends of Alg-MA and Alg-MA-Ox materials. The control and modified alginate 
solutions were blended with photo-activators to enable photo-crosslinking (See Appendix  
VII for detailed protocol):  1 mM Eosin Y (photo-sensitizer), 125 mM triethanolamine 
(photo-initiator), 20 mM 1-vinyl-2-pyrrolidinone (catalyst).16, 23-24 Aliquots of 580 µL 
were placed within a 27 µm gap between the Peltier plate and cone geometry. Shear 
sweeps were performed to determine the viscosity (Pa.s) and shear stress (Pa) of the 
alginate-based solutions at 1% radial strain, 1-100 (1/s), over one min (n = 4). Data was 
analyzed using analytical software (TA Data Analysis); data sets for various samples 
within a single group are merged and sorted by shear rate, and plotted on the same graph.  
 
Oscillatory time sweeps at 10% radial strain and 1 Hz were conducted on 
alginate-based hydrogel precursor solution during exposure to green light (525 nm, 
custom 9.84 cm diameter LED ring, NFLS-G30X3-WHT, SuperBrightLEDs) over a 
period of 10 minutes (600 seconds).15 Data collection started upon the start of light 
exposure (i.e., photo-crosslinking activation). Shear storage (G′) and loss (G″) moduli 
were calculated, and tan delta (ratio of G″ to G′) was analyzed using analytical software 
(TA Data Analysis).  
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4.3.4. Burst pressure testing and failure analysis 
Burst pressure values were determined using ASTM F2392 as a guide.30 Burst 
pressure was recorded using a custom-designed pressure-chamber testing device 
according to the ASTM standard (Figure 7).  
 
Figure 7: Schematic illustration of experiment setup for mechanical burst pressure testing of 
alginate-based sealants. 
 
The main chamber was machined from polyether ether ketone (PEEK) to 
provide low cost fabrication and fluid-related degradation resistance; it was designed to 
be two sections fastened by two bolts with a fluoroelastomer o-ring to provide an airtight 
seal, for easy specimen loading between the sections.  A syringe pump (Harvard 
Apparatus PHD 2000 Infusion) controlled the fluid injection rate into the chamber; for 
this experiment we used air pressure. A pressure transducer (Omega PX-409-
030AUSBH) was connected to the pressure chamber through a NPT port, allowing for 
accurate, real-time data acquisition via a connected computer (Figure 7). 
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Collagen substrates (collagen casing, The Sausage Maker Inc.) were hydrated in 
DI water and tested on the pressure device before creating a defect (i.e., puncture) to 
ensure that the substrate was intact and void of defects, and formed a leak-free seal. The 
substrates were punctured with a 3 mm diameter biopsy punch and re-tested to ensure a 
through-thickness defect was formed resulting in a drop in pressure (or the inability to 
hold pressure). Punctured collagen substrates were clamped between a glass slide and a 
Teflon mold, with a 1.5 cm diameter hole, centered over the collagen puncture. Hydrogel 
precursor solution (0.5 mL) was deposited into the mold, over the collagen puncture, and 
photo-crosslinked for 10 minutes under visible green light (523 nm). The collagen 
substrate with the hydrogel sealant was removed from the mold and loaded onto the burst 
pressure device. Air volume, via the syringe pump, was increased at a constant air flow 
rate into the pressure chamber, until the seal failed; failure was defined as a loss in 
pressure due to a leak in seal (i.e., experimental sample). All burst pressure tests were 
conducted at room temperature with compressed air at an infusion rate of 75 mL/hr. 
 
The hydrogel sealant failure mechanism, either hydrogel delamination from the 
collagen substrate or hydrogel material failure (i.e., failure of the material under loading), 
was assessed via visual inspection of the hydrogel materials and a digital microscope 
(Dino-Lite Pro AM413TA, Dino-Lite Digital Microscopes) during and after testing. 
Video was collected directly above the burst pressure device for the duration of the test. 
The digital microscope was positioned 10-15 cm above the hydrogel sealant, and 
recording was initiated just prior to the activation of the syringe pump and halted several 
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seconds after sealant failure (Supplemental Video 1 has been edited to show failure 
activity). Delamination, i.e., adhesive failure, was classified as bond failure between the 
sealant and substrate, whereas material failure was classified as bond failure within the 
material itself.  
 
4.4. Results and Discussion 
4.4.1. Rheology 
The chemical modification of alginate, and other polysaccharides, may induce 
chain scission and a reduction in molecular weight of the alginate backbone; polymer 
degradation depends on the nature of the chemical reaction.8, 22, 27-28 Also, sequential 
chemical reactions will affect the degree of modifications of various functional groups. 
Therefore, DOO and DOM were calculated for each modified alginate formulation. All of 
the Alg-MA starting materials had a DOM = 77; however, as evidenced by the DOM 
calculations performed on the Alg-MA-Ox materials, the oxidation reaction slightly 
reduced the DOM, as shown in Table 1.  
Table 1: Summary of the chemical characterization, burst pressure values, and mode of failure for 
Alg-MA, Alg-MA-Ox, and homogenous 50:50 polymer blends of Alg-MA and Alg-MA-Ox hydrogel 
sealants. 
Group DOM (%) DOO (%) G’ (Pa) at t = 600 s 
Burst Pressure 
(mmHg) 
Principal  
Mode of Failure 
Alg-MA 77 0 ~1560 49.41 ± 22.46 D 
10 Alg-MA-Ox 70 10 ~113 26.11 ± 13.13 M 
30 Alg-MA-Ox 64 25 <0.01 7.09 ± 9.85 M 
10 Alg-MA-Ox Blend 74 5 ~440 48.04 ± 10.64 M 
30 Alg-MA-Ox Blend 71 13 ~235 35.40 ± 10.66 M 
50 Alg-MA-Ox Blend 54 20 ~150 27.66 ± 12.36 M 
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Physical changes, such as a reduction in molecular weight, result in variable 
mechanical responses. Thus, we quantified viscosity and shear stress after each chemical 
reaction; the effects of shear rate on the viscosity and shear stress of 3% (w/v) alginate 
solutions are shown in Figure 8.  
 
 
Figure 8: (A) Viscosity (Pa.s) and (B) shear stress (Pa) values were collected for alginate-based tissue 
sealant precursor solutions, including: Alg-MA, oxidized Alg-MA, and homogenous 50:50 blends of 
Alg-MA and Alg-MA-Ox. Representative plots for each control and experimental group are shown 
as average values (n = 4). 
 
 
Solution viscosities decreased exponentially with increasing shear rates for all 
solutions tested. Compared to non-modified alginate solutions (i.e., controls), the 
methacrylated alginate (Alg-MA) solution maintained high viscosities and shear stresses 
(Figure 8). In contrast, the oxidized and methacrylated alginate (Alg-MA-Ox) solutions 
demonstrated much lower viscosities and shear stresses when compared to alginate and 
Alg-MA solutions. Methacrylation chemistry is deleterious to the alginate backbone, 
although this is more pronounced in Alg-MA-Ox materials.8, 27-28 During the oxidation 
reaction, alginate molecular weight was reduced, and resulted in a > 100-fold reduction in 
viscosity. During the oxidation reaction, Alg-MA was exposed to high concentrations of 
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sodium periodate to open the uronate residues on the acidic repeat units, rendering the 
polymer reactive with ECM proteins (i.e., imine formation) through the introduction of 
aldehyde functional groups.22, 34  Additionally, the oxidation of alginate increases 
susceptibility to hydrolytic degradation, improving biodegradability of the sealant.8 Thus, 
tissue adhesion and in vivo degradation time can be controlled through the optimization 
of the addition and creation of acrylate and aldehyde functionalities to alginate. Adhesion 
may be further assisted through the formation of weak hydrogen bonds between the 
biomacromolecules comprising the sealant and the proteins present on the tissue 
surface.35 
 
To effectively seal a leak or damaged tissue, a liquid tissue sealant must display 
a relatively high viscosity to maintain a film over a tissue defect during the gelation, or 
curing, process. While the Alg-MA-Ox material is required to maintain adhesion to 
underlying tissue, the requirements of the amount and/or degree of oxidation have not 
been studied. Thus, Alg-MA was blended with Alg-MA-Ox materials to enhance the 
viscosity of the solutions and further improve material properties. Alg-MA and Alg-MA-
Ox blends (1:1) were created from the same formulation of Alg-MA, and different Alg-
MA-Ox polymers with varying degrees of oxidation (10, 30 and 50%). Upon blending 
Alg-MA with Alg-MA-Ox, viscosity and shear stress values were partially recovered 
compared to Alg-MA-Ox solutions. The viscosity and shear stress values for all of the 
polymer blend solutions were similar, suggesting that the properties of the Alg-MA 
polymer were dominant and served as an equalizing agent (see Figure 8). 
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4.4.2. Visible light crosslinking and gelation time 
Alg-MA and Alg-MA-Ox solutions, in the presence of photo-activators, were 
crosslinked and formed into hydrogels upon exposure to green light. The gelation times 
of the hydrogel solutions were determined from oscillatory time sweep plots (Figure 9).  
 
 
Figure 9: Gelation of alginate-based sealants were assessed using oscillatory time sweeps at 10% 
radial strain and 1 Hz during exposure to green light (525 nm) over a period of 10 minutes. (A, B) 
Alg-MA and oxidized Alg-MA, and (C, D) homogenous 50:50 blends of Alg-MA and Alg-MA-Ox. 
Delta values decreased as crosslinking occurred via visible light exposure to form hydrogels (A, C). 
Storage moduli values, G', and loss moduli values, G", were collected during gelation (B, D). 
Representative plots for each control and experimental group are shown as average values (n = 4). 
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The initiation of gelation, i.e., gelation time, was determined to be at the 
inflection point of the delta versus time curve. The Alg-MA solution and Alg-MA-Ox 
polymer blend solutions indicate a clear inflection in the delta curve, indicative of 
successful photo-initiation and subsequent crosslinking. The Alg-MA-Ox solutions with 
DOO ≥ 30 failed to form a gel (i.e., photo-crosslink) rheometry. The storage moduli 
curves versus time are a more reliable indicator for terminal crosslinking as it plateaus 
and indicates no further crosslinking (Figure 9B, D). Upon inspection of the G′ curves, a 
majority of the crosslinking was completed by 600 seconds, and increased by several 
orders of magnitude. Thus, an exposure time of 10 minutes (600 seconds) was used to 
form hydrogels for burst testing.  
 
4.4.3. Burst pressure properties  
To perform effectively, a tissue sealant must adhere to underlying tissue and 
exhibit material strength exceeding physiological loading conditions. Burst pressure 
measurements and the subsequent failure analysis quantified the ability for alginate-based 
hydrogels to perform as tissue sealants under increasing pressure. Two modes of failure, 
delamination of the material from the substrate, and material rupture due to a loss in 
strength, were determined via video during experimentation (Figure 10A). Representative 
pressure versus time curves from burst pressure testing are shown in Figure 10B.  
 
While the Alg-MA hydrogel saw the highest individual burst pressure, it was 
also the only material to fail by delamination. Burst volume measurements were 
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calculated based on the amount of air pumped into the device before failure. The burst 
pressure volumes relate to the qualitative flexibility of the tissue sealant (Figure 10C). 
Comparing the 10 Alg-MA-Ox and 10 Alg-MA-Ox blend sample groups, the flexibility 
of the blend material resulted in a higher burst pressure and burst volume.  
 
 
Figure 10: Failure analysis data of alginate-based tissue sealants using a burst pressure device and 
test system. (A) High-speed video captured the qualitative mode of failure for a sealed 3 mm 
diameter hole. The two modes of failure observed were delamination, D, and material failure, M. (B) 
Burst pressure data is shown as strain to failure with time. While the pressure input rate was 
constant, materials responded according to their elasticity. Burst pressure was recorded as the 
highest pressure achieved. Vertical error bars represent burst pressure standard deviation; 
horizontal error bars represent time to failure (n = 4). (C) Total air volume retained in the device 
before failure was calculated; averages including standard deviations are reported (n = 4). 
 
As the DOM decreases, the number of methacrylate functional groups available 
for covalent crosslinking decreases. With less methacrylate groups available, the resulting 
polymerized hydrogel is more loosely bound together than its highly methacrylated 
counterpart. Polymer networks that are more loosely bound behave more as a viscous 
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material rather than an elastic material, and exhibit lower storage moduli, as shown in 
Error! Reference source not found. (see above). Because our polymer hydrogels rely 
more on elastic than viscous behavior, post-crosslinking, for its application as a sealant, it 
is expected that storage modulus would correlate with burst pressure. The relation 
between DOM, storage modulus, and burst pressure are highlighted in Error! Reference 
source not found.. 
 
Delamination, or adhesive failure, occurred when the hydrogel patch separated 
from the substrate with no visible sign of material damage (Figure 10A). Material failure 
was characterized as the failure of the sealant material immediately above the puncture, 
and showing visible damage to the material (Figure 10A). The Alg-MA hydrogel sealants 
failed exclusively through delamination, while the Alg-MA-Ox materials exhibited 
material failure, with the exception of a single 10 DOO Alg-MA-Ox:Alg-MA blend 
experimental group. Alginate is inherently non-adhesive, and there are few forces 
keeping the Alg-MA hydrogel sealant adhered to the collagen substrate. However, the 
Alg-MA-Ox hydrogels and blends interact with the collagen substrate through functional 
aldehyde groups, preventing delamination before material failure. The only case of 
delamination outside the Alg-MA group occurred in the blend with the lowest theoretical 
DOO, resulting in fewer aldehyde groups to interact with the substrate, possibly 
explaining the delamination. In summary, aldehyde functionality is required to ensure 
adhesion and the formation of a seal. However, the optimum DOO required for 
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maintaining tissue adhesion while exhibiting high burst pressures has yet to be 
determined.  
 
4.5. Conclusions 
Alginate, a biomacromolecule derived from brown algae, was investigated as a 
hydrogel tissue sealant. Chemical modifications were tuned to optimize the mechanical 
and adhesive properties, which are essential in developing a tissue sealant. Specifically, 
methacrylation resulted in acrylate groups that were photo-responsive in the presence of 
photo-activators and visible green light. Alginate oxidation created aldehyde groups for 
sealant-substrate interactions and increased adhesion to tissue matrix proteins. A custom-
designed burst pressure device was fabricated and implemented in the mechanical 
analysis of alginate-based hydrogel sealants. While Alg-MA hydrogels were able to 
withstand high pressures without mechanically failing, these materials delaminated from 
the substrate and failed adhesively. Conversely, Alg-MA-Ox formed hydrogels that 
adhered to the substrate; however, these materials failed at lower burst pressures. Alg-
MA and Alg-MA-Ox polymer blends benefited from the high mechanical strength of the 
Alg-MA and the adhesiveness of the Alg-MA-Ox. Most notably, higher DOO Alg-MA-
Ox did not result in improved adhesion, which may also be the result of polymer 
degradation during the oxidation reaction. Indeed, minimal oxidative degradation (1-5% 
DOO) is required to induce hydrogel sealant adhesion while maintaining hydrogel 
network integrity.  
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CHAPTER 5 : DUAL-CROSSLINKED METHACRYLATED ALGINATE SUB-
MICROSPHERES FOR INTRACELLULAR CHEMOTHERAPEUTIC 
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5.1. Abstract  
Intracellular delivery vehicles comprised of methacrylated alginate (Alg-MA) 
were developed for the internalization and release of doxorubicin hydrochloride (DOX). 
Alg-MA was synthesized via an anhydrous reaction, and a mixture of Alg-MA and DOX 
was formed into sub-microspheres using a water/oil emulsion. Covalently crosslinked 
sub-microspheres were formed via exposure to green light, in order to investigate effects 
of crosslinking on drug release and cell internalization, compared to traditional 
techniques such as ultra violet (UV) light. Crosslinking was performed using light 
exposure alone, or in combination with ionic crosslinking using calcium chloride (CaCl2). 
Alg-MA sub-microsphere diameters were between 88 – 617 nm, and zeta-potentials were 
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between -20 and -37 mV. Using human lung epithelial carcinoma cells (A549s) as a 
model, cellular internalization was confirmed using flow cytometry; different sub-
microsphere formulations varied the efficiency of internalization, with UV-crosslinked 
sub-microspheres achieving the highest internalization percentages. While blank (non-
loaded) Alg-MA sub-microspheres were non-cytotoxic to A549s, DOX-loaded sub-
microspheres significantly reduced mitochondrial activity after five days of culture. 
Photo-crosslinked Alg-MA sub-microspheres may be a potential chemotherapeutic 
delivery system for cancer treatment. 
 
5.2. Introduction 
Lung cancer is one of the most widespread type of carcinoma, resulting in the 
largest number of cancer-related deaths around the world.1-3 Greater than 85% of lung 
cancer cases are currently classified as non-small-cell lung cancer (NSCLC), including 
adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma. Despite the recent 
advances in early detection and cancer treatment, NSCLC is often diagnosed at an 
advanced stage and has a poor prognosis.1 Chemotherapy is one of the current 
recommended treatments to prevent or reduce tumor-induced symptoms, prolong patient 
survival, and maintain patient quality of life.4 Chemotherapy treatments can last as long 
as 6 months at high parenteral dosages, and are frequently associated with systemic 
toxicity.5-6  
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Doxorubicin hydrochloride (DOX) is one of the most widely used 
chemotherapeutic drugs, and is known as an anthracycline antibiotic.7 The main anti-
cancer mechanisms that have been suggested for DOX fall into the following categories: 
1) DOX intercalation into DNA, shutting down protein synthesis and DNA replication; 2) 
DOX-induced production of reactive oxygen species (ROS), inducing DNA damage 
and/or lipid membrane peroxidation; 3) DNA crosslinking, binding and alkylation; 4) 
DOX interference with DNA unwinding, strand separation and helicase activity; 5) 
damage to the bilayer structure of cell membranes; 6) DNA inhibition of topoisomerase 
II, initiating DNA damage pathways. All the above activities require that DOX be 
presented inside the cytoplasm,8-10 which requires intracellular delivery of DOX to cancer 
cells. DOX treatment induces several side effects including nausea, vomiting, and fever 
in patients.11 A significant incidence of cardiovascular side effects – hypotension, 
tachycardia, arrhythmias, and ultimately congestive heart failure – are also reported.8, 12 
Therefore, there is a need for drug delivery systems which efficiently encapsulate and 
deliver chemotherapeutics while reducing adverse events. As a small molecule, concerns 
of low encapsulation efficiency, drug leakage, and aggregation limit the therapeutic 
efficacy of DOX, and complications associated with sterilization have not been resolved.5  
 
Modern drug delivery systems are designed to maintain the structure and 
bioactivity of biomolecules and to release therapeutics in a controlled and predictable 
manner. Micro-encapsulation is one of the core technologies used in polymer drug 
delivery systems.13 However, the relatively large micron-size (> 10 µm) of the drug 
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delivery particles limits cellular internalization. Therefore, the association of DOX to 
sub-micron carriers has drawn greater interest,14 including liposomes,15 nanospheres and 
sub-microspheres,16 and micelles.17 
 
Alginate is an unbranched polysaccharide consisting of 1→4 linked β-D-
mannuronic acid (M) and its C-5 epimer α-L-guluronic acid (G). Alginate is extracted 
from brown seaweed, and has been investigated for biomedical and pharmaceutical 
applications due to its relatively low cost, low toxicity, biocompatibility, and 
biodegradability.18-21 Alginate particles have increasingly been shown to offer 
controllable drug encapsulation efficiencies and release profiles, while maintaining the 
bioactivity of various drugs, including proteins,22 cytokines,23 and small molecules.24 
Through the formation of a water/oil emulsion and subsequent exposure to calcium ions, 
alginate particles within the micrometer – nanometer size scale can be generated, and are 
often referred to as ionically crosslinked alginate particles.20, 22, 25  
 
The fabrication of alginate microspheres and sub-microspheres is favorable for 
drug delivery due to the relatively mild ionic gelation process.22, 26 However, limitations 
associated with the relatively weak ionic bonds include low drug encapsulation efficiency 
and rapid drug-release rates (< 24 h).27 To overcome these limitations, methacrylated 
alginate (Alg-MA) was synthesized 28 and sub-microspheres were generated utilizing a 
water/oil emulsion 22 and subsequent crosslinking. Alg-MA sub-microspheres were 
covalently crosslinked using photoinitiators and visible (i.e., green) or UV light 
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irradiation.28 Dual-crosslinked sub-microspheres were generated with the subsequent 
addition of calcium chloride.22 To evaluate the efficiency of internalization and the 
bioactivity of DOX-loaded Alg-MA sub-microspheres, human lung epithelial carcinoma 
cells (A549s) were utilized as a model system. We hypothesized the dual-crosslinking 
would result in a tighter hydrogel network for more efficient intracellular DOX delivery 
(Figure 11). DOX encapsulation efficiency and in vitro release were quantified using an 
absorbance assay. While blank (non-loaded) Alg-MA sub-microspheres were non-
cytotoxic to A549s, DOX-loaded sub-microspheres significantly reduced mitochondrial 
activity after five days of in vitro culture.   
 
Figure 11: Schematic of the hydrogel network structure comprising photo-crosslinked and dual-
crosslinked Alg-MA sub-microspheres. (I) Photo-crosslinked sub-microspheres exhibit a porous 
hydrogel network with intermolecular covalent crosslinks, encapsulating DOX. (II) Upon the 
addition of ionic crosslinking, the hydrogel network tightens, resulting in reduced drug loss and 
slower diffusion-based drug release; this is the desired product. (III) However, the introduction of 
aqueous-based calcium chloride (CaCl2) solution may result in drug loss during the ionic crosslinking 
step. (IV) The non-ideal dual-crosslinked product may exhibit lower drug loading capacity due to the 
additional steps in the fabrication process. 
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5.3. Materials & Methods 
5.3.1. Materials and reagents 
Sodium alginate (MW = 65–75 kg/mol, 60-70% guluronic acid residues) was 
generously donated by FMC BioPolymer. Irgacure D2959 was generously donated by 
Ciba Inc. Biology-grade mineral oil, Span  80, Tween 80, ethylenediaminetetriacetic acid 
(EDTA), deuterium oxide (D2O), dimethyl sulfoxide (DMSO, 99% anhydrous), 
dodecyltrimethylammonium bromide salt (DTAB), methacrylic anhydride (MA), 4-
(dimethylamino)pyridine (DMAP), DOX, N-ethyl-N’(3-dimethylaminopropyl) 
carbodiimide hydrochloric acid (EDC), N-hydroxysuccinimide (NHS), and an in vitro 
toxicology assay kit (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT)-based) were purchased from Sigma-Aldrich. One molar hydrochloric acid (HCl) 
and 1 M sodium hydroxide (NaOH) were purchased from BDH ARISTAR®PLUS. 
Dichloromethane (DCM, 99.9%), sodium citrate, isopropanol, calcium chloride (CaCl2), 
sodium chloride (NaCl), sodium citrate, Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F-12) mammalian cell culture medium, Alexa Fluor® 647 
cadaverine and 20X phosphate buffered saline (PBS) were purchased from Fisher 
Scientific. Fetal bovine serum (FBS) was purchased from Atlanta Biologics. Penicillin, 
streptomycin, and 0.25% trypsin EDTA were purchased from Corning Cellgro. A549 
(CCL-185™) human lung epithelial carcinoma cells were purchased from ATCC®.  
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5.3.2. Synthesis and characterization of methacrylated alginate (Alg-MA) 
Alg-MA was synthesized utilizing an anhydrous reaction to control the degree 
of methacrylation (DOM).28-29 Sodium alginate was rendered soluble in anhydrous 
DMSO through an ion exchange with DTAB. Aqueous solutions of sodium alginate (1%, 
w/v) and DTAB (2%, w/v) were prepared and slowly mixed while stirring at 1000 
rotations per minute (See Appendix III for detailed protocol). The precipitate was washed 
in DI water and lyophilized. A 1% (w/v) alginate-DTA/DMSO solution was reacted with 
MA in the presence of a catalyst, DMAP, for 24 hours at room temperature (See 
Appendix IV for detailed protocol). The solution was hydrolyzed through extensive 
dialysis in 0.2 M sodium phosphate dibasic salt solution followed by further dialysis in 
DI water. Alginate methacrylation was confirmed using 1H-NMR spectroscopy, (Bruker 
AVANCE III 500 MHz high-field NMR spectrometer) by the presence of methacrylate 
(6.25, 5.75 ppm) and alginate methyl resonances (2.0 ppm). A 1% (w/v) polymer solution 
in D2O was analyzed at room temperature, spinning at 20 Hz for 16 scans.28, 30 The DOM 
was quantified by peak integration and calculation of the ratio between of the methyl 
protons at 2.0 ppm and the newly formed methylene protons of methacrylate at 5.75 ppm 
and 6.25 ppm.30-31 
 
5.3.3. Dual-crosslinked Alg-MA sub-microsphere design and fabrication  
Aqueous Alg-MA solutions were mixed with photoinitiators for UV (0.05%, 
w/v, Irgacure D2959) or visible green light activation [1 mM eosin Y (photosensitizer), 
125 mM triethanolamine (initiator) and 20 mM 1-vinylpyrrolidone (catalyst)], 
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respectively. Two percent (w/v) Alg-MA solutions were mixed with 0.1% (w/v) DOX 
and formed into sub-microspheres using a water/oil emulsion and subsequent 
crosslinking (Figure 12).  
 
Figure 12: (A) Chemical structure of methacrylated alginate (Alg-MA). Alg-MA was covalently 
crosslinked in the presence of photoinitiators under light activation, to form photo-crosslinked Alg-
MA hydrogel networks. Alg-MA hydrogels were ionically crosslinked in the presence of calcium 
chloride (CaCl2) to form dual-crosslinked Alg-MA hydrogel networks. (B) Schematic representation 
of microsphere fabrication techniques. Microspheres with or without DOX were prepared by 
premixing Alg-MA solutions and creating a water/oil emulsion at room temperature. Alg-MA sub-
microspheres were photo-crosslinked upon exposure to visible or UV light, respectively, and further 
dual-crosslinked in the presence of 1 M CaCl2. 
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Alg-MA sub-microspheres without DOX were fabricated as blank (i.e., non-
loaded) controls.22 One milliliter of polymer/DOX solution was slowly added to 6.72 mL 
of biological-grade mineral oil containing 5% (v/v) Span 80, while mixing at 1200 rpm 
for 5 minutes at room temperature. Subsequently, 400 µL of 30% (v/v) Tween 80 (in 
biological-grade mineral oil) was added and mixed for an additional 5 minutes. 
Crosslinking was performed four different ways: 1) green light exposure for 10 minutes 
(Green, using 525 nm wavelength, NFLS-G30 3-WHT, SuperBrightLEDs); 2) UV light 
exposure for 10 minutes (UV, using 320–390 nm wavelength, Uvitron Intelliray 400); 3) 
green light plus 5 mL of 0.5 M CaCl2, mixing for 15 minutes (Green+C); and 4) UV light 
plus 5 mL of 0.5 M CaCl2, mixing for 15 minutes (UV+C).28  After crosslinking, 3 mL of 
isopropanol was added to the emulsion and mixed for 5 minutes, then centrifuged at 400 
rpm for 5 minutes to precipitate sub-microspheres. Alg-MA sub-microspheres were 
washed sequentially with isopropanol (x2) and DI water (x2), respectively, and 
centrifuged after each wash.  
 
The diameters and zeta-potentials (i.e., surface charge) for hydrated, blank and 
DOX-loaded Alg-MA sub-microspheres were quantified using dynamic light scattering 
(DLS, Zetasizer Nano ZSP, Malvern). Sub-microspheres were suspended in PBS, pH = 
7.4, at room temperature. Hydrodynamic diameters were determined based on number 
averages, and the size distribution was plotted for each sub-microsphere group. After 
lyophilization, Alg-MA sub-microspheres were characterized by scanning electronic 
microscopy (SEM, JEOL 600); samples were sputter coated with 45 nm of Au-Pb prior to 
 101 
 
imaging. SEM micrographs of various magnifications were used to visualize or attempt 
to visualize Alg-MA sub-microspheres. 
 
5.3.4. Drug loading and mechanisms of release 
Covalently and/or dual-crosslinked Alg-MA sub-microspheres were evaluated 
for use as chemotherapeutic delivery vehicles. DOX was utilized as a model drug for its 
intrinsic UV absorbance and ease of quantification, for drug encapsulation, drug release 
and effectiveness assays. To determine whether or not UV or green light exposure 
changed the chemical structure or bioactivity of DOX, aqueous DOX solutions were 
exposed to UV and green light for 10 minutes, and then characterized by 1H-NMR, using 
non-modified DOX as a control. DOX encapsulation efficiency, i.e., drug retention 
during sub-microsphere fabrication, was calculated as a percentage of the initial loading 
concentration. Covalent crosslinking of the sub-microspheres prevents dissolution; 
therefore, an extended diffusion process was utilized to quantify encapsulated drug. 
Briefly, 1 mg of sub-microspheres was suspended in 1 mL of PBS, incubated at 37°C and 
agitated for three weeks. The solution was centrifuged, and the supernatant was analyzed 
on a microplate reader (Synergy HT microplate reader, BioTek) at 485 nm absorbance, 
and compared to standard curve (EE = Actual Drug Encapsulated ÷ Theoretical Drug 
Loaded). Detection of drug lost during washing procedures was not possible due to 
presence of multiple phases of emulsion additives and the absorbance detection limit of 
DOX on the equipment utilized. 
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To characterize in vitro release profiles, released DOX concentration was 
quantified using the intrinsic absorbance at 485 nm in a 48-well tissue culture polystyrene 
(TCPS) plate at 37°C (Synergy HT microplate reader, BioTek). One milligram of 
lyophilized DOX-loaded Alg-MA sub-microspheres was dissolved in 500 µL of PBS, pH 
7.4 (n = 3). At 1, 2, 4, 8, 12, and 24 hours, and daily up to 11 days, 100 µL of PBS was 
removed for analysis, and replaced with 100 µL of fresh PBS to maintain the total 
volume. DOX concentration was determined using an absorbance assay and generating a 
standard curve. Cumulative DOX (µg) released over time was calculated by adding the 
mass of DOX released at each time point per mass of sub-microspheres.  
 
5.3.5. Cellular uptake of Alg-MA sub-microspheres 
Four different formulations of blank (i.e., non-loaded) Alg-MA sub-
microspheres were reacted with Alexa Fluor® 647 cadaverine dye to form fluorescent 
sub-microspheres (Alexa 647-Alg-MA); the surface reaction chemistry was performed 
according to the manufacturers protocol through carbodiimide chemistry at room 
temperature catalyzed by NHS/EDC. Alg-MA sub-microspheres without DOX were used 
in order to avoid cell death during internalization and analysis. A549s were seeded in 48-
well TCPS plates at 25,000 cells/well in 500 µL/well of standard growth culture medium 
(DMEM/F-12, 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin), and allowed to 
adhere for 24 hours at 37°C and 5% CO2. Cells were then incubated with blank Alexa 
647-Alg-MA sub-microspheres (n = 6 per group) at 100 µg/mL, 37°C and 5% CO2. After 
12 hours, culture medium containing Alexa 647-Alg-MA sub-microspheres was 
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removed, and adherent cells were thoroughly rinsed with PBS three times to remove non-
internalized and cell-surface-bound sub-microspheres. Cells were trypsinized and re-
suspended in PBS at 1x106 cells/mL, and analyzed by flow cytometry (BD LSRII Flow 
Cytometer) to quantify the percentage of A549s that internalized the sub-microspheres. 
A549s cultured with no sub-microspheres, and cells cultured with non-fluorescent sub-
microspheres, were prepared and analyzed as controls.22 
 
5.3.6. Cytotoxicity of blank and drug-loaded Alg-MA sub-microspheres  
The cytotoxicity of blank (i.e., non-loaded) and DOX-loaded sub-microspheres 
was evaluated using a toxicology, MTT-based assay. A549s were seeded in 48-well 
TCPS plates at 25,000 cells/well in 500 µL/well of standard growth culture medium, and 
allowed to adhere for 24 hours at 37°C and 5% CO2. Cells were then incubated in the 
presence of blank Alg-MA sub-microspheres or DOX-loaded Alg-MA sub-microspheres 
(n = 6 per group, per fabrication type) at sub-microsphere concentrations of 10, 50, 100 
µg/mL. After 24 hours, medium containing sub-microspheres (blank groups and DOX-
loaded groups) was removed, cells were rinsed two times in sterile PBS, and then 
analyzed using a MTT-based assay according to the manufacturer’s protocol. The optical 
density was measured at 570 nm; background absorbance at 690 nm was subtracted from 
the measured absorbance at 570 nm (Synergy HT microplate reader, BioTek). 
Absorbance values for the experimental samples were normalized to controls and 
reported as normalized mitochondrial activity.22 
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5.3.7. Effect of intracellular vs. extracellular drug delivery on cell proliferation 
The bioactivity of the DOX-loaded sub-microspheres was evaluated using a 
similar method discussed in section 2.6.1.  A549s were seeded in 48-well TCPS plates at 
10,000 cells/well in 500 µL/well of standard growth culture medium, and allowed to 
adhere for 24 hours. Cells were incubated in the presence of DOX-loaded Alg-MA sub-
microspheres (n = 6 per fabrication type) at sub-microsphere concentrations of 10, 50, 
and 100 µg/mL. A549s and Alg-MA sub-microspheres were co-cultured for 5 days with 
media exchanges. Free DOX (i.e., DOX contained within the cell culture medium) was 
added to A549s at different concentrations (5, 4, 3, 2, 1, 0.5, 0.25, 0.125, 0.06, 0.03, 
0.015 and 0 µg/mL) to compare the effect of intracellular versus extracellular DOX 
delivery. After 1, 3 and 5 days of culture, a MTT-based assay was performed according 
to the manufacturer’s protocol, to quantify the effects of DOX-loaded Alg-MA sub-
microspheres and free DOX on in vitro cancer cell proliferation. Absorbance values for 
the experimental samples were normalized to controls and reported as normalized 
mitochondrial activity.22 
 
5.3.8. Data analysis 
The quantitative results for all experiments are reported as mean ± standard 
deviation. Statistical analysis was performed on Alg-MA sub-microsphere co-cultured 
cell assays, using one-way ANOVA with DUNNETs method (α = 0.05) via the SAS 
statistics program in the GLM procedure, as the post-test to compare all of the groups. A 
p < 0.05 was considered significantly different. 
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5.4. Results & Discussion 
5.4.1. Synthesis and characterization of Alg-MA 
The chemical modification of alginate rendered it hydrophobic and soluble in 
organic solvents. An anhydrous methacrylation of alginate resulted in a functionalized 
biomacromolecule with a controllable DOM.28 1H-NMR spectra for Alg-MA and non-
modified alginate are shown in Figure 13. The DOM for the Alg-MA used as the base 
material in the sub-microspheres was approximately 64%.31-33 Peaks between 3.0 and 3.5 
ppm indicate methyl groups at the end of alginate chains resulting from degradation 
during the methacrylation chemistry.  
 
 
Figure 13: The 1H-NMR spectra of Alg-MA and alginate are shown. The peaks at 5.75 and 6.25 ppm 
indicate that the hydrogens on the methylene of the methacrylate groups were present on the alginate 
backbone after modification. The degree of methacrylation was calculated to be 64%. 
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5.4.2. Fabrication and characterization of dual-crosslinked Alg-MA sub-
microspheres 
The formation of Alg-MA sub-microspheres was indicative of a crosslinked 
hydrogel network, obtained through either covalent crosslinking34 (e.g., via photo-
crosslinking) alone, or in combination with ionic crosslinking (e.g., by the addition of 
CaCl2), as illustrated in Figure 12.27, 34-35 The DOM for the Alg-MA base material was 
64%, and this moderate-DOM sustained both covalent and ionic crosslinking. Photo-
crosslinking occurred upon UV or green light activation between adjacent acrylate 
groups, while the subsequent presence of CaCl2 induced ionic crosslinking between 
adjacent carboxyl groups. While methacrylation took place at available hydroxyl groups, 
ionic crosslinks formed between adjacent carboxyl side-groups on neighboring alginate 
chains, thus allowing Alg-MA to sustain dual-crosslinking.  
 
DOX-loaded sub-microsphere hydrodynamic diameters were quantified using 
DLS analysis (Table 2). The largest populations of DOX-loaded sub-microspheres were 
sized between 243 – 391 nm: UV = 243 nm, Green = 391 nm, UV+C = 346 nm, Green+C 
= 358 nm. The variability of the sub-microsphere diameters, plotted as size distributions 
in Figure 14A+B, is an almost unavoidable result of the emulsion process, and is indeed a 
limitation of the fabrication method; however, the linear size distribution plots indicate 
the following: Alg-MA sub-microspheres exhibited size populations within the same size 
scale, thus demonstrating consistency in fabrication method. SEM images (Figure 15) 
also indicated that Alg-MA sub-microspheres were spherical in shape, however 
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heterogeneous in size. The zeta-potentials ranged between -20 mV and -37 mV, and none 
of the groups demonstrated any significant outlying data. 
Table 2: Dynamic light scattering (DLS) quantitative analysis of hydrodynamic diameters and zeta-
potentials of blank (i.e., non-loaded) and DOX-loaded photo-crosslinked and dual-crosslinked Alg-
MA sub-microspheres. DOX encapsulation efficiencies were determined using an absorbance assay 
after sub-microsphere fabrication. 
Sub-Microsphere 
Group 
Hydrodynamic Diameter by 
Number (nm) Zeta-Potential (mV) 
Encapsulation  
Efficiency (%) 
Blank DOX Loaded Blank DOX Loaded DOX Loaded 
Green Light 334 391 -37 -27 28 
UV Light 331 243 -21 -21 84 
Green Light + Calcium 88 358 -29 -33 26 
UV Light + Calcium 197 346 -27 -25 3 
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Figure 14: Dynamic light scattering size distribution plots for photo-crosslinked and dual-crosslinked 
Alg-MA sub-microspheres both non-loaded/blank (A) and DOX-Loaded (B): green photo-crosslinked 
(Green), green + Ca2+ dual-crosslinked (Green+C), UV photo-crosslinked (UV), UV + Ca2+ dual-
crosslinked (UV+C). Hydrodynamic diameters were based on number-average calculations. 
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Figure 15: Scanning electron microscopy (SEM) images representing dehydrated, Alg-MA sub-
microparticles for qualitative assessment of morphology. 
 
5.4.3. Swelling and diffusion-based drug release 
The efficacy of Alg-MA sub-microspheres as chemotherapeutic delivery 
vehicles was investigated. DOX was utilized as a model drug for its intrinsic UV 
absorbance and ease of quantification for subsequent drug encapsulation, drug release 
and effectiveness assays. Alg-MA sub-microspheres were designed to encapsulate DOX 
without interfering with the detectability or bioactivity of DOX. Both photo-crosslinking 
alone or dual-crosslinking were successful in fabricating DOX-loaded sub-microspheres. 
The low level of UV or green light exposure required for sub-microsphere fabrication did 
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not change the chemical structure of DOX, verified by 1H-NMR spectroscopy (Figure 
16), and the toxic effects of DOX were still active.36 The mild-gelation techniques used to 
form Alg-MA sub-microspheres may retain the functionality and bioactivity of other 
therapeutics. Indeed, it was hypothesized that secondary, ionic crosslinking may show no 
beneficial effect on DOX encapsulation efficiency, however, the effect of ionic 
crosslinking may result in sustained drug release due to a tighter hydrogel network 
structure.  
 
Figure 16: The 1H-NMR spectra of DOX solutions before and after light exposure are shown in 
Supplemental Figure S3. No significant differences are present in the spectra for UV and green light 
exposed DOX solutions and the spectrum for the non-modified DOX solution, showing molecular 
structure and bioactivity are preserved. 
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The cumulative mass of DOX released over time was calculated from four 
different types of Alg-MA sub-microspheres, and release profiles are shown in Figure 17. 
The DOX release profiles followed two different trends – a linear release profile was seen 
during the first 8 hours of release, consistent with hydrogel-swelling induced drug release 
(see Figure 17A). Cumulative DOX release profiles through 11 days are shown in Figure 
17B. The release profiles for UV, Green, and Green+C groups followed a logarithmic 
trend (trend line R2 ≥ 0.92), while the UV+C group followed a linear release profile up to 
11 days (trend line R2 = 0.98); however, these trends were not analyzed further. The 
amount of DOX released did show a similar trend with encapsulation efficiencies: dual-
crosslinked sub-microspheres encapsulated less drug and released less drug over an 11 
day period.37-38 The introduction of aqueous-based CaCl2 solution to the emulsion 
resulted in drug loss due to DOX solubility in aqueous solutions.39  
 
Figure 17: Quantitative cumulative release of doxorubicin (DOX) from Alg-MA sub-microspheres 
for 11 days (average ± standard deviation, n = 6 hydrogel samples per group). Various formulations 
of sub-microspheres were assessed: green photo-crosslinked (Green), green + Ca2+ dual-crosslinked 
(Green+C), UV photo-crosslinked (UV), UV + Ca2+ dual-crosslinked (UV+C). Sample aliquots were 
collected and the DOX concentration was determined using a standard curve at an absorption 
wavelength of 485 nm. (A) Cumulative DOX release profile during the first 8 hours. (B) Cumulative 
DOX release profile during 11 days. 
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The varying release kinetics with time suggest that the sub-microsphere 
structure may be optimized further for controlled release applications, by varying the 
degree of crosslinking to extend or delay the drug release rate.34 It is hypothesized that 
increasing the drug-loading concentration, increased efficacy over longer time periods 
could be achieved. Decreasing the variability in the diameter of the sub-microspheres and 
varying the Alg-MA DOM may also result in varied release rates due to changes in the 
network microstructure. However, sub-microsphere size homogeneity and drug release 
profile optimization were outside the scope of this study and may be addressed through 
further investigations.  
 
5.4.4. Cellular uptake of Alg-MA sub-microspheres  
Uptake of Alg-MA sub-microspheres into A549s was quantitatively determined 
via flow cytometry to detect the fluorescent signal of Alexa-647-labeled sub-
microspheres. Non-treated A549s and cells cultured with non-fluorescently labeled sub-
microspheres were used as controls. Utilizing gate settings based on the fluorescent 
intensity level of the probe, negative and positive populations were established, and it 
was found that all four types of Alg-MA sub-microspheres were readily internalized by 
A549s.22 The positive population was > 80% in all four treatment groups (Figure 18A-F). 
UV crosslinked Alg-MA sub-microspheres (single and dual-crosslinked) exhibited higher 
internalization rates compared to green light crosslinked groups (Figure 18G), which may 
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be related to sub-microsphere diameter; however, statistics were not performed on the 
internalization data.  
 
Figure 18: Flow cytometry analysis of Alg-MA sub-microspheres after 12 hours of co-culture with 
human lung epithelial carcinoma (A549) cells. (A) Non-treated cell control, (B) cells cultured with 
non-labeled blank sub-microspheres, (C) cells cultured with green photo-crosslinked sub-
microspheres, (D) cells cultured with green photo-crosslinked and calcium crosslinked sub-
microspheres, (E) cells cultured with UV photo-crosslinked sub-microspheres, and (F) cells cultured 
with UV photo-crosslinked and calcium crosslinked sub-microspheres. (G) Flow cytometry 
histograms were presented to show the different fluorescence intensity between control cells and 
different Alg-MA sub-microsphere groups. 
 
5.4.5. Cytotoxicity of blank and drug-loaded Alg-MA sub-microspheres  
To verify the non-toxicity and retention of DOX bioactivity after sub-
microsphere encapsulation, MTT assays were performed on blank Alg-MA sub-
microspheres and DOX-loaded Alg-MA sub-microspheres after 24 hours of culture with 
A549s to quantify mitochondrial activity. A549 viability was assessed in the presence of 
Alg-MA sub-microspheres at increasing concentrations (10, 50, 100 µg/mL, Figure 19). 
Blank Alg-MA sub-microspheres (with no drug content) were minimally cytotoxic to 
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A549s (mitochondrial activity > 80%) at concentrations up to 100 µg/mL (Figure 19A). 
Increased mitochondrial activity may be attributed to low molecular weight soluble 
alginate (i.e., sugar) in the culture media. Additionally, we hypothesize the reduced 
cytotoxicity seen in the UV+C group may be due to enhanced clearance of residual UV 
photoinitiator upon secondary crosslinking with an aqueous calcium chloride solution.40 
DOX-encapsulated sub-microspheres delivered bioactive drug, significantly reducing 
mitochondrial activity within 24 hours (Figure 19B). 
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Figure 19: Human lung epithelial carcinoma (A549) cells were cultured in the presence of hydrogel 
sub-microspheres for 24 hours in standard growth culture medium at 37˚C and 5% CO2. A549 
mitochondrial activity was determined using an absorbance-based quantitative assay; absorbance 
data for the groups treated with sub-microspheres were normalized to the non-treated cell control 
(average ± standard deviation, n = 6 hydrogel samples per group). The cytotoxicity of Alg-MA sub-
microspheres was analyzed on (A) blank (non-loaded) sub-microspheres. The bioactivity of 
doxorubicin (DOX) was verified using (B) DOX-loaded sub-microspheres. Various groups (white 
diamonds = green photo-crosslinked, white circles = UV photo-crosslinked, black diamonds = green + 
Ca2+ dual crosslinked, black circles = UV + Ca2+ dual crosslinked) and sub-microsphere 
concentrations (10, 50, 100 µg/mL) were characterized. 
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5.4.6. Effect of intracellular vs. extracellular drug delivery on cell proliferation 
Four different types of DOX-loaded Alg-MA sub-microspheres were cultured 
with A549s at concentrations of 10, 50 and 100 µg/mL. In addition, different 
concentrations of free DOX was added to the culture media and served a control. A short-
term cell proliferation study (utilizing an MTT assay) was performed for 5 days. On day 
1, all of the Alg-MA sub-microsphere groups reduced A549 proliferation, regardless of 
the crosslinking type or concentration (Figure 20A). On days 3 and 5, the UV crosslinked 
Alg-MA sub-microspheres showed the greatest reduction in the A549 proliferation. For 
comparison, normalized mitochondrial activity was plotted versus free DOX, Figure 20B, 
or DOX-loaded sub-microspheres calculated, Figure 20C.  
 
Compared to the free DOX control, Alg-MA sub-microsphere-mediated delivery 
shows a similar decreasing trend as drug concentration increases, though remains less 
effective. Also, it is likely that drug remains within the sub-microspheres and is not 
released intracellularly. Another consideration is that due to the extended drug release 
profile of DOX from sub-microspheres (Figure 17B), improved efficacy beyond 5 days 
may be achieved. Indeed, photo-crosslinked microspheres alone are advantageous for 
delivering a chemotherapeutic to cancer cells, at clinically-relevant dosages, and 
decreased lung cancer cell mitochondrial activity.  
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Figure 20: The efficacy of doxorubicin (DOX)-loaded Alg-MA sub-microspheres as 
chemotherapeutic delivery vehicles was assessed using a MTT-based assay, to quantify cell 
proliferation over a 5-day period.  A549 activity was recorded as mitochondrial activity and 
normalized to non-modified cell controls. Various formulations and concentrations (10-100 µg/mL) 
of sub-microspheres were assessed: green photo-crosslinked (Green), green + Ca2+ dual-crosslinked 
(Green+C), UV photo-crosslinked (UV), UV + Ca2+ dual-crosslinked (UV+C). DOX was added 
exogenously (Free DOX) to the cell culture medium at various concentrations to test the effect of 
intracellular versus extracellular DOX delivery. (A) Effect of Alg-MA sub-microsphere 
concentration for each crosslinking type on A549 mitochondrial activity; (B) Effect of ‘free dox’ 
concentration on A549 mitochondrial activity on days 1, 3, and 5; (C) Effect of DOX concentration 
encapsulated within Alg-MA sub-microspheres on A549 mitochondrial activity on days 1, 3, and 5. 
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5.5. Conclusions 
The study reported here-in focused on the efficacy of utilizing crosslinked Alg-
MA sub-microspheres to intracellularly deliver a chemotherapeutic. Photo-crosslinked 
and dual-crosslinked Alg-MA sub-microspheres successfully encapsulated DOX, were 
internalized by A549s, and delivered DOX to A549s, reducing mitochondrial activity 
compared to non-modified cell controls. The outcome of this study suggests that photo-
crosslinking alone, and in particular green light activation, is an effective means of 
producing drug delivery vehicles, and perhaps additional crosslinking steps or procedures 
are not beneficial, perhaps even detrimental, to drug encapsulation efficiencies. Based on 
drug encapsulation predictions and calculations, effective clinical drug dosages were 
achieved, as compared to free DOX delivery, and were controllable. While the efficacy 
for using photo-crosslinking Alg-MA sub-microspheres was shown during a short time 
frame (5 days) in vitro, future in vivo work may show enhanced drug efficacy using 
microsphere-mediated delivery compared to exogenous intravenous chemotherapy over 
extended periods of time. Further discussion of this work can be found in Appendix XI. 
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CHAPTER 6: THERAPEUTIC ALGINATE-BASED ADHESIVE HYDROGELS 
FOR LUNG TISSUE REPAIR 
 
Spencer L. Fenn, Patrick Charron, Rachael A. Oldinski 
 
 
Contributions 
The research discussed in this chapter was performed by the first author, 
Spencer L. Fenn. The first author was also responsible for manuscript drafting and figure 
development with input and revisions being provided by the second author, Patrick N. 
Charron, and the senior author Rachael A. Oldinski.  
 
6.1 Abstract 
Injury to the connective tissue that lines the lung, the pleura, or to the lung itself 
can occur from many causes including trauma or surgery, as well as lung diseases or 
cancers. Bronchopleural fistulas, malignant pleural effusions, and traumatic or ventilator-
induced pleural injuries are a continuing source of morbidity, mortality, and increased 
health care expenditures in the clinic. There are currently only limited methods of 
patching significant injuries to stop the air or fluid leak quickly and subsequently allow 
for healing processes to repair the underlying tissue. We have devised an adherent 
hydrogel sealant patch system, based on the blending of methacrylated alginate (AMA) 
and AMA di-aldehyde (AMA-DA), which is capable of sealing damaged tissues and 
sustaining physiological pressures. Methacrylation of alginate hydroxyl groups rendered 
the polysaccharide capable of photo-crosslinking when mixed with an eosin Y based 
photoinitiator system and exposed to visible green light. To improve tissue adhesion, 
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oxidation of alginate was performed, opening uronate residues on the carbohydrate 
backbone to yield functional aldehyde groups capable of imine bond formation with 
proteins found in many tissues. These two chemical modifications, when utilized in 
combination, allow for the synthesis of an adhesive hydrogel sealant. The resulting bulk 
material was subsequently mixed at various ratios and concentrations, blended with 
photoinitiators and fabricated into film patches using a manual injection molding 
technique. To test efficacy of the alginate-based patch system, a custom burst pressure 
testing device was designed and fabricated according to ASTM Standard F2392-04R10, 
utilizing punctured collagen casings as a test substrate. High-speed videography was 
performed during each test to assess the mechanism of failure, either adhesive failure 
(delamination from the substrate), or material failure (burst through the patch). Cell 
viability and cytotoxicity were assessed using human mesothelial cells (MeT-5A, ATCC) 
after 24 hours culture in the presence of test materials.  Additionally, drug-eluting 
adhesive patches were fabricated through incorporation of doxorubicin encapsulating 
nanoparticles, and used to successfully treat human lung cancer cells (A549, ATCC). 
 
 124 
 
 
6.2. Introduction 
Lung leaks, due to damage in the pleural lining or resected tissue, are a major 
medical problem thoracic surgeons are currently facing, and are associated with increased 
morbidity, mortality, and health care costs. Trauma or complications of pulmonary 
surgery can result in air or liquid leaking out of the lung and into the pleural space, i.e., 
chest cavity, decreasing lung volume and causing the lung to collapse (pneumothorax), 
ultimately requiring emergent placement of a chest tube, an invasive approach associated 
with complication and limitations, to re-inflate the lung. 
 
Chronic pleural effusions related to underlying lung cancers or cancers 
metastatic to lung (malignant effusions) are especially difficult to treat, apart from 
surgical interventions or pleurodesis. Physical pleurodesis is a surgical technique 
involving suturing or pleural abrasion procedures through the use of thoracotomy.1 
Chemical pleurodesis consists of applying a nocuous material, such as talc, on the lung 
wall to cultivate the inflammatory response.2-3 
 
Few effective means exist of patching the injury to stop the air or fluid leak and 
allow appropriate healing to occur. Approaches using glues or other sealants applied 
either directly to the lung surface or instilled into the airways have not been widely 
successful to date. In addition, prolonged tissue damage due to an underlying disease, 
infection or cancer has not been addressed by the current methods. Few-effective options 
are available and new therapeutic approaches are desperately needed. 
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Indeed, surgical sealants tools available to surgeons when closing or sealing 
surgical sites or wounds in tissue, yet due to the dynamic movement and stretch imposed 
on lung tissues, few have shown efficacy at physiological lung pressures. Hydrogels are 
natural or synthetic-based crosslinked polymer networks that swell but do not dissolve in 
aqueous media. While the use of hydrogels as surgical sealants and wound treatments 
began developing in the 1960’s, the use of hydrogels to treat pulmonary and alveolar air 
leaks initiated in the late 1980’s.4 Natural based biomaterials are advantageous compared 
to their synthetic counterparts due to heightened compatibility, degradability, sustainable 
resources, and intrinsic bioactive qualities. Alginate and alginate-based hydrogels are 
investigated for biomedical applications due to their inherent non-toxicity, 
biocompatibility, and are readily available.5 Derived from brown algae, alginate is 
desirable not only for those attributes already listed, but also for its relatively low cost 
and the various applications it can be used for drug delivery and tissue engineering.6 
Chemical modification of alginate has been studied extensively for improving upon the 
physical and mechanical properties of ionically crosslinked alginate gels.7-9 
Methacrylation of alginate imparts a functional group capable of light-activated covalent 
crosslinking by free radical polymerization in the presence of a photoinitiator. Alginate is 
inherently non-adhesive; however, oxidation of the backbone structure will elicit 
functional groups capable of forming crosslinks with extracellular matrix proteins, such 
as those found on the pleural surface. 10-13 
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In order to treat lung leaks, we ultimately aim to develop a sealant that not only 
provides a reliable seal, but that can also control the release of soluble drugs and growth 
factors to treat disease and/or stimulate tissue regeneration. We illustrate the ability to 
control therapeutic drug release through nanoencapsulation techniques and subsequent 
mixing with the polymer precursor solutions prior to tissue sealant patch fabrication.  
 
6.3. Materials and Methods 
6.3.1. Synthesis of methacrylated alginate (AMA)  
Methacrylated alginate (AMA) was synthesized as previously described.5, 14 
Briefly, a 2% (w/v) solution of Manugel® GMB (MW≈ 170-240 kDa, FMC Biopolymer) 
in deionized water was mixed with a 20-fold molar excess of methacrylic anhydride 
(Sigma-Aldrich). The solution was maintained at pH 8 using 5 N sodium hydroxide 
(Fisher) for 24 hours. Purification was performed via dialysis (MWCO=6000-8000 Da) 
against deionized water for 5 days, and lyophilized to yield a dry product. A 1% (w/v) 
AMA was prepared in deuterium oxide (Acros Organics) and subsequently analyzed 
using 1H-NMR spectroscopy (Bruker AVANCE III 500 MHz high-field NMR 
spectrometer), for 64 scans at 20 Hz. The degree of methacrylation (DOM) was 
established through integration of the peaks associated with methacrylate (6.24, 5.78 
ppm) and alginate methyl resonances (1.96 ppm), and calculation of the ratios between.14-
16 
 
6.3.2. Synthesis of methacrylated alginate dialdehyde (AMA-DA) 
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To retain the ability to photo-crosslink while simultaneously improving the 
adhesive properties to tissue/proteins, AMA was oxidized to yield AMA dialdehyde or 
(AMA-DA). A 1% AMA solution was prepared in deionized water and reacted with 
sodium periodate (Sigma) at 0.25% (w/v) or 0.5% (w/v) to yield AMA-DA solutions with 
theoretical degrees of oxidation (DOO) of 25% (AMA-25DA) and 50% (AMA-50DA) 
respectively.11-14, 17 The products were dialyzed against deionized water for 48 hours, and 
lyophilized to obtain dry AMA-DA. 1% (w/v) AMA-DA solutions were prepared in 
deuterium oxide (Acros Organics) and subsequently analyzed using 1H-NMR 
spectroscopy (Bruker AVANCE III 500 MHz high-field NMR spectrometer), for 64 
scans at 20 Hz.  The degree of oxidation (DOO) was calculated by taking integrals of the 
alginate methyl protons at 5.0 ppm and the newly formed methyl protons at 5.17, 5.48 
and 5.68 ppm and subsequent comparison of ratios.12-13 
 
6.3.3. Visible light crosslinking and hydrogel formation  
 AMA and AMA-DA solutions were analyzed using a rheometer 
(AR2000, TA Instruments) to if functionalization modulated the physical and mechanical 
properties of the molecules in solution or crosslinked as hydrogels. The viscosity and 
gelation kinetics of Alg, AMA, and AMA-DA precursor solutions and resulting 
hydrogels were determined. All tests were performed at 37°C using a 20-mm diameter 
1°59’6” steel cone geometry with a truncation gap of 57 µm; 6% (w/v) polymer solutions 
were prepared in PBS with photo-initiators added at the following final concentrations:1 
mM Eosin Y (photo-sensitizer, Acros Organics), 125 mM triethanolamine (initiator, 
Sigma), 20 mM 1-vinyl-2-pyrrolidinone (catalyst, Sigma).18-20 Viscosity was measured at 
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shear rates ranging from 1-100 (1/s), over a 60 second time period, using non-crosslinked 
precursor solutions. Gelation kinetics of the precursor solutions were assessed using an 
oscillatory time sweep at 10% radial strain at 1 Hz during exposure to visible green light 
(525 nm, custom 9.84 cm diameter light emitting diode (LED) array, NFLS-G30X3-
WHT, SuperBrightLEDs) for a total of 5 minutes (300 seconds).16 Shear storage (G′) and 
loss (G″) moduli, as well as tan delta (ratio of G″ to G′) were calculated using analytical 
software (TA Data Analysis).  
 
6.3.4. Hydrogel Patch Fabrication 
Lung sealant patches were fabricated using an injection molding technique. 
Polymer solutions (3% and 6% w/v) in deionized water were prepared using AMA, 
AMA-25DA, AMA-50DA and subsequently blended at 1:1 or 1:2 ratio. Polymer 
solutions were then supplemented with photo-initiators as described in Section 2.3 and 
were protected from exposure to light.  
 
Precursor solutions were injected between two sheets of polytetrafluoroethylene 
(Teflon™) with a 1 mm spacer, using a syringe and 20-gauge needle, taking care to avoid 
the formation of air-bubbles. The mold was then rapidly frozen using liquid nitrogen 
(vapor phase) and freeze-dried using a lyophilizer (Freezone, Labconco). Once dry, the 
mold was disassembled and the newly formed dry sheet of material was cut into 
individual patches using circular biopsy punches. It is important to note that at this stage, 
the patches have not yet undergone photo-crosslinking yet contain photo-initiators 
required to induce photo-crosslinking once exposed to visible green light. 
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Figure 21: Fabrication of tissue sealant patches is performed using an injection molding technique in 
combination with lyophilization to form dry sheets of sealant material which can be cut to size using 
a biopsy punch. 
 
6.3.5. Assessment of material cytotoxicity  
To assess the cytotoxicity of AMA and AMA-DA patches, MeT-5A human 
mesothelial cells (ATCC® CRL9444™) were cultured in the presence of test materials 
over a 24-hour period (n=3). Mesothelial cells were maintained at 37°C and 5% CO2 in 
Medium 199 (Sigma) supplemented with the following components: 10% fetal bovine 
serum (FBS, Hyclone), 3.3 nM epidermal growth factor (EGF, Sigma), 400 nM 
hydrocortisone, 870 nM bovine insulin (Sigma), 20 mM HEPES (Sigma), 3.87 µg/L 
selenious acid (Aldrich), Trace Elements B Liquid used at 1,000 dilution (Corning).  Cell 
viability, cytotoxicity and apoptosis were assessed using an ApoTox-Glo™ Triplex 
Assay (Promega Corporation) according to the manufacturers protocol, and metabolic 
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activity was assessed using an thiazolyl blue tetrazolium bromide (MTT, Sigma) based 
assay. Cells were treated with 10 mg/mL AMA, AMA-25DA and AMA-50DA.  
 
After 24-hours culture with test materials, the ApoTox-Glo™ 
viability/cytotoxicity reagent was prepared and added to each well per the manufacturers 
protocol allowed to culture at 37°C for an additional 30 min. At this time, the plate was 
assessed using a plate reader (H1 Synergy, BioTek) measuring fluorescence intensity at 
the following excitation and emission wavelengths listed in nanometers: 400Ex/505Em 
(viability) and 485Ex/520Em (cytotoxicity). Successively the apoptosis reagent was 
prepared, added to each well, and allowed to culture for an additional 30 minutes at room 
temperature. Luminescence was then read using a plate reader. 
 
After 24-hours of culture with test materials, a previously prepared MTT-
solution in PBS was added to each test well, up to a final concentration of 0.5 mg/mL, 
mixed briefly on an orbital shaker, and incubated at 37°C for 3-hours. Next, the cell 
culture media and excess MTT-solution were aspirated from each well and replaced with 
dimethyl sulfoxide (DMSO, Sigma) to solubilize the formazan crystals using gentle 
orbital shaking. Absorbance was assessed at 540 nm wavelength, the peak absorbance of 
formazan in DMSO, using a plate reader. Background absorbance was assessed at 690 
nm wavelength and subtracted from the absorbance observed at 540 nm to obtain a 
corrected absorbance reading of cell mitochondrial activity. 
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6.3.6. Burst pressure and sealant failure analysis 
To assess the performance of sealant patch formulations, ASTM F2392-04 was 
modified to build and utilize a custom-built burst pressure testing device, as previously 
described and depicted.14, 21 Briefly, a polyether ether ketone device was designed to 
securely fasten a membrane/substrate across an open chamber, using a fluoroelastomer o-
ring and clamp, which can be pressurized using an air-filled syringe and syringe pump 
(PHD 2000 Infuser, Harvard Apparatus). Pressures within the chamber were recorded 
digitally using a USB-connected pressure transducer (Omega PX-409-030AUSBH) 
attached to the chamber through a side NPT-port. The entire apparatus was housed in an 
incubator held at 37°C. High-speed video (120 frames per second) is recorded during 
testing using a camera (Hero4, GoPro) with attached macro lens which has been mounted 
within the incubator. This video is utilized to assess the mechanism of failure, either 
adhesive failure (delamination) or material failure (burst).14  
 
Collagen-rich substrates (Collagen Casings, The Sausage Maker Inc.) were used 
as an in vitro test membrane per the standard.21 Each substrate was hydrated in PBS at 
37°C for at least 30 minutes prior to testing. To verify each substrate was free from 
defects and leaks, the substrate was first clamped down in the device and pressurized to 
12 in-H2O at an infusion rate of 75 mL/hr, and held briefly ensuring no change in 
pressure (i.e., no leaking occurred). Once substrate integrity was confirmed, the 
membrane was removed from the device and a small defect was created in the membrane 
using a 1.5 mm diameter biopsy punch. Over these defects 8 mm diameter sealant patches 
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were applied, and hydrated using 20 µL of PBS at 37°C. The sealant was then photo-
crosslinked for 5 minutes using a custom LED array (525 nm, NFLS-G30X3, 
SuperBrightLEDs). Once cured, the now-sealed membrane was returned to the burst-
pressure testing apparatus and pressurized at 75 mL/hr until failure of the sealant was 
observed. 
 
6.3.7. In vitro degradation study 
To assess the effects of degradation on hydrogel mass and swell ratios, 
crosslinked hydrogels fabricated from 6% AMA:AMA-25DA at 1:1 ratio were first 
weighed (dry), and subsequently placed in cell culture media in a shaker-incubator at 
37°C for 14 days. On days 1, 3, 7, and 14, samples were removed and weighed (wet), 
freeze-dried, then weighed (dry) to obtain both swell ratios and changes in mass.  
 
6.3.8. Fabrication of doxorubicin-loaded nanoparticles 
A 2% (w/v) AMA solution was prepared in deionized water, and subsequently 
supplemented with 0.1% (w/v) doxorubicin hydrochloride (DOX, Sigma).15 Additionally, 
photo-initiators were added to the mixture, as listed in Section 2.3. Drug-encapsulated 
hydrogel nanoparticles were formed using a water-in-oil emulsion technique and 
covalently photo-crosslinked using visible green light.15, 22 At room temperature, one mL 
of DOX-loaded polymeric precursor solution was added dropwise to 6.75 mL of 
bioreagent-grade mineral oil containing 5% (v/v) Span 80, consistently mixing at 1200 
rpm with a egg-shaped stir bar for 5 minutes. Next, 400 µL of 30% (v/v) Tween 80 (in 
bioreagent-grade mineral oil) was added and mixed for a further 5 minutes. At this point, 
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the emulsion droplets were photo-crosslinked for 5 minutes using visible green light 
produced by a custom LED-array (525 nm wavelength, NFLS-G30 3-WHT, 
SuperBrightLEDs). Particles were washed in isopropanol (2x) and de-ionised water (2x), 
using high-speed centrifugation between each washing step, and subsequently freeze-
dried for storage. Particle size in PBS (pH 7.4) was assessed using dynamic light 
scattering (DLS, Zetasizer Nano, Malvern) at 37°C. 
 
6.3.9. Fabrication of drug eluting sealant patch 
Polymeric precursor solutions were prepared as described in Section 2.4 for the 
two highest performing formulations, 6% AMA:AMA-25DA and 6% AMA:AMA-50DA 
blended at a 1:1 weight ratio, and were subsequently blended with 800 µg/mL DOX-
encapsulated nanoparticles. The solutions were quickly injected into molds (see Section 
6.3.4. ), frozen, and lyophilized to form DOX-eluting sealant patches. 
 
6.3.10 Chemotherapeutic drug release 
To assess drug-release kinetics of the DOX-eluting patches, 10 mg patches each 
containing approximately 160 µg DOX-nanoparticles, were prepared from the molded 
sheet using a biopsy punch, and placed in a 48-well plate. The patches were hydrated 
with 50 µL PBS (pH 7.4), and crosslinked for 5 minutes. Subsequently, 500 µL PBS was 
added to each well, and the entire plate was placed in an incubator shaker at 37°C at 30 
rotations per minute (rpm). At 1, 2, 4, 6, 12, 24, 48 hours, 100 µL of supernatant were 
collected from each well and immediately replaced with 100 µL of fresh PBS.15 To 
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quantify cumulative drug released at each time point, the absorbance of collected aliquots 
was assessed at 485 nm wavelength using a plate reader and compared to a DOX 
standard curve.15, 23 Peak absorbance of DOX in PBS (pH 7.4) was previously confirmed 
to be 485 nm when assessed using an absorbance spectral sweep from 300-700 nm at 1 
mg/mL concentration (Figure 22). 
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Figure 22: Verification of the peak absorbance of doxorubicin hydrochloride was performed via a 
spectral sweep at 1 mg/mL in PBS (pH 7.4). The peak absorbance is shown at 485 nm wavelength 
which will be used for subsequent drug-release assays. 
 
6.3.11. Bioactivity of chemotherapeutic patch 
The bioactivity of the DOX-eluting patches was assessed using human lung 
epithelial carcinoma cells (A549, ATCC). Cells were seeded in the lower portion of a 48-
well Transwell® plate (0.4 µm pore diameter)  at 25,000 cells per well, and allowed to 
adhere to substrate overnight at 37°C in Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F-12, Gibco) mammalian cell culture medium supplemented with 
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10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin. Prior to starting the assay, 
10 mg patches, containing 160 µg of DOX-encapsulating nanoparticles each, were 
hydrated and photo-crosslinked on the permeable membrane insert of the Transwell® 
plate (n=3 per group), and subsequently added to the seeded wells. After 24 hours of 
culture at 37°C, viability was assessed as previously described in Section 2.5. 
 
6.3.12. Statistical analysis 
All numerical results are presented as a mean ± standard deviation unless 
otherwise stated. A one-way ANOVA with Dunnett’s method for multiple comparisons 
was utilized for viability, cytotoxicity, apoptosis and MTT assays. A one-way ANOVA 
with Tukey’s method for multiple comparisons was used for burst pressure data analysis. 
A p-value of 0.05 or less was considered statistically significant for all statistics 
performed. 
 
6.4. Results 
6.4.1. Synthesis of AMA and AMA-DA 
Alginate methacrylation was performed to enable covalent photo-crosslinking 
between adjacent polysaccharide chains in aqueous solutions, forming a hydrogel.5, 9, 12, 
14-15, 24-31 The aqueous methacrylation chemistry yielded a functionalized 
biomacromolecule capable of covalent crosslinking, as confirmed by 1H-NMR (see 
Figure 23). The degree of methacrylation (DOM) was calculated to be 58% for AMA, 
and 36% and 38% for AMA-25DA and AMA-50DA respectively. The degree of 
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oxidation (DOO, i.e. aldehyde-modification) was calculated to be 19% for AMA-25DA 
and 42% for AMA-50DA. 
 
Figure 23: A) Molecular repeat units for sodium alginate, methacrylated alginate, and methacrylated 
alginate dialdehyde are presented. B) The 1H-NMR spectra of 25% and 50%  oxidized AMA-DA, 
AMA and unmodified alginate are shown as labelled. Peaks of interest identified with arrows. The 
peaks at 5.78 and 6.24 ppm indicate that the hydrogens on the methylene of the methacrylate groups 
were present on the alginate backbone after modification. The degree of methacrylation for AMA  
was calculated to be 58%. The peaks at 5.17, 5.48 and 5.68 ppm are indicative of oxidation and the 
opening of the uronate residues to form aldehyde groups. The experimental degree of oxidation for 
the 25 DOO and 50 DOO AMA-DA were calculated to be 19% and 42% respectively Degrees of 
methacrylation were found to decrease after oxidation/aldehyde-modification to 38% and 36% 
respectively. 
 
6.4.2. Rheology 
Viscosities for 6% w/v polymer solutions are presented in Figure 24, over a 
range of increasing shear rates. AMA solutions (blue circles) demonstrated the highest 
viscosity over all shear rates tested. Significant decreases in viscosity were observed after 
oxidation of AMA, to yield functional aldehyde groups, as shown by AMA-25DA (red 
square) and AMA-50DA (green triangle), with viscosity decreasing more with higher 
levels of oxidation. The decrease in viscosity was partially recovered when blended with 
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non-oxidized AMA, as shown by both 1:1 blends presented (orange diamond, violet 
triangle). 
 
 
Figure 24: Viscosity of 6% w/v polymer solutions was assessed over shear rates of 1-100 (1/s) at 37°C 
and shown in log10 scale. Notice the viscosity decreases significantly for the oxidized/aldehyde-
modified solutions, but is partially recovered when blended with AMA at a 1:1 ratio. 
 
6.4.3. Visible light crosslinking and gelation kinetics 
Oscillating a shear force during hydrogel crosslinking reveals the sealants 
gelation kinetics. Storage modulus, or G’, is a measurement of the elastic response of the 
material, and will increase as crosslinking between adjacent polysaccharide chains and 
their methacrylate side-groups occurs, resulting in a plateau when crosslinking has 
reached its terminal maximum. In Figure 25, G’ values are presented and show similar 
plateauing behavior after 100 seconds for all groups tested. Non-oxidized AMA exhibited 
the highest storage moduli after 5 minutes of crosslinking, followed by the AMA-DA 
blends, and lastly the pure AMA-DA exhibited the lowest moduli. 
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Figure 25: Gelation kinetics were assessed by oscillatory time sweeps at 10% radial strain and 1 Hz 
frequency while pre-cursor solutions were exposed to visible green light (525 nm) and maintained at 
37°C. Storage moduli (G’) of 6% w/v polymer solutions is shown over a 5 minute (300 s) period.  
 
 
6.4.4. Hydrogel Patch Fabrication 
Thin polymer films were successfully formed using an injection molding 
technique, followed by subsequent lyophilization (Figure 26A&B). These films contain 
all photoinitiators required for crosslinking to form a hydrogel, when hydrated and 
exposed to visible green light (Figure 26C). Due to the blending of AMA and AMA-DA 
in the fabrication process (as denoted in Table 3), the DOM and DOO varied between 
each formulation. The DOM and DOO for each patch formulation was calculated and is 
listed in Table 3. 
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Figure 26: A&B) Dry sheet of non-crosslinked sealant material after injection molding and 
lyophilization. This material can be cut to required size, and contains all required initiators for 
visible green light photo-crosslinking. C) Hydrated and crosslinked adhesive hydrogel on fingertip. 
 
Table 3: Summary of patch formulations tested, including polymer concentrations, blend ratios, 
degrees of methacrylation (DOM) and oxidation/aldehyde-modification (DOO), average burst 
pressures achieved prior to failure, and the mode of sealant failure (delamination/adhesive-failure is 
denoted by D, and material failure/rupture is denoted by M) 
Conc. 
(% w/v) Formulation 
Blend 
Ratio 
DOM 
(%) 
DOO 
(%) 
Average Burst 
Pressure (inH2O) 
Predominant 
Mode of Failure 
3 
AMA n/a 58 0 41.0 ± 23.7 D 
AMA:AMA-25DA 1:1 48 10 7.7 ± 8.4 M 
AMA:AMA-50DA 1:1 47 21 5.3 ± 6.6 M 
4.5 
AMA n/a 58 0 51.8 ± 34.9 D 
AMA:AMA-25DA 1:1 48 10 25.3 ± 5.8 M 
AMA:AMA-50DA 1:1 47 21 5.9 ± 7.48 M 
AMA:AMA-25DA 1:2 45 13 20.6 ± 13.8 M 
AMA:AMA-50DA 1:2 43 28 12.0 ± 3.9 M 
AMA:AMA-25DA 2:1 51 6 65.3 ± 50.3 D 
AMA:AMA-50DA 2:1 51 14 77.3 ± 53.3 D 
6 
AMA n/a 58 0 142.0 ± 34.5 D 
AMA:AMA-25DA 1:1 48 10 200.8 ± 11.9 M 
AMA:AMA-50DA 1:1 47 21 119.2 ± 21.6 M 
 
 
6.4.5. Cell viability, apoptosis, and material cytotoxicity  
After 24 hours exposure to the hydrogel patch material (not containing DOX), 
no statistically significant decreases in mesothelial cell viability were observed (Figure 
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27A), though significant increases in cell viability were witnessed by the cells exposed to 
AMA and AMA-50DA. Similarly, though no significant increases in cytotoxicity were 
observed in the cells exposed to sealant materials, significant decreases in cytotoxicity 
are shown in both AMA and AMA-50DA groups (Figure 27B) which aligns with 
viability test results. Cell metabolism as indicated by mitochondrial activity is often used 
as an indicator of cytotoxicity and proliferation using MTT-based assays.15-16, 32-34 MTT 
is metabolized by the cell mitochondria resulting in the formation of formazan crystals 
which can subsequently be dissolved and quantified via absorbance detection on a plate 
reader. Increased formazan concentrations result in heightened absorbance, signifying 
higher mitochondrial activity, and decreased cytotoxicity. No significant differences in 
cell apoptosis or mitochondrial activity were found with any test material (Figure 27C & 
D).
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Figure 27: (A) Viability, (B) cytotoxicity, (C) apoptosis and (D) mitochondrial activity as 
demonstrated human mesothelial cells after 24 h exposure to sealant patch materials as compared to 
non-treated control.  Increases in overall cell viability were shown in AMA and 25% oxidized AMA-
DA, simultaneously showing decreased cytotoxicity when compared to control. No significant 
differences in apoptosis and mitochondrial activity was observed.  
 
6.4.6. Burst pressure properties  
Burst pressure testing of alginate-based sealant patches yielded pressures at 
failure ranging from 5-200 in-H2O as shown in Figure 28. A red dotted-line is shown at 
12 inH2O, representing the normal maximum physiological lung pressure, and acts as a 
threshold which must be achieved for the sealant to be considered for the desired 
application.14 Although several 3% and 4.5% w/v formulations achieve average burst 
pressures above this threshold value, the variation (as shown by standard deviation error 
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bars) disqualifies many of these formulations as they do not provide any margin of error. 
The only groups which consistently yielded burst pressures above the threshold with 
acceptable levels of variation were the 6% w/v formulations, of which the AMA:AMA-
25DA 1:1 blend performed significantly better than the other tested 6% w/v formulations 
with an average burst pressure above 200 in-H2O.  
 
 
Figure 28: Burst pressure at 
failure is shown for all tested 
formulations in inH2O. 
Physiological lung pressures 
typically remain below 12 
inH2O, which is denoted with a 
red dotted-line. Statistical 
significance is shown between 
specific groups using an 
asterisk. 
 
 
 
 
 
 
The mechanism of sealant failure was assessed using high-speed videography. 
Material failure  occurs when a rupture is formed through the sealant material, with the 
sealant maintaining adhesion to the substrate, as indicated in Figure 29A by a small 
perforation. Adhesive failure, or delamination, occurs when the sealant peels off of the 
substrate, either partially or completely (as shown in Figure 29B). The predominant mode 
of failure for each patch formulation is listed in Table 3. Sealants blended with AMA-DA 
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were more prone to material failure (rupture), while pure AMA-based sealants failed 
exclusively through adhesive failure (delamination) due to lack of crosslinking to the 
substrate. Blends of AMA and AMA-DA at a 1:2 ratio failed predominantly via material 
failure, though reverted to adhesive failure when blended at an inverse ratio of 2:1. 
 
Adhesive Failure 
(Delamination)
Material Failure 
(Rupture)
Intact Sealant
Intact Sealant
A
B
 
Figure 29: Graphic representations of both mechanisms of sealant failure. (A) Material failure 
occurs when a rupture is formed through the sealant material, yet the patch remains adhered to the 
surrounding substrate. (B) Adhesive failure occurs when the patch delaminates, either partially or 
completely (as shown above), from the substrate beneath. 
 
6.4.7. Degradation of alginate-based sealant patches 
Over a 14-day period, sealant patches made from 6% w/v AMA:AMA-25DA 
blended at a 1:1 ratio, lost over 50% of their initial dry mass (Figure 30A). Swell ratios 
also decreased significantly during the 14-day period (Figure 30B), from 2667% to 
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1902%, which relates to the decrease in water-retaining polysaccharide content. Visual 
changes in appearance can also be observed, with pitting and surface erosion observed on 
the hydrogel patch surface (Figure 30C). 
 
 
Figure 30: The effects of degradation were assessed using 6% w/v sealant patches over a 14 day 
period at 37°C. (A) Mass decreased by more than 50% over the two-week period. (B) Similarly, swell 
ratios decreased dramatically over the 14 day period due to the reduction in polysaccharide 
molecules retaining water. (C) Images of gel patches on day 1 and 14 are presented. After 14 days of 
degradation, visible pitting/surface-erosion can be observed on the surface of the hydrogel. 
 
6.4.8. Doxorubicin encapsulating nanoparticle size evaluation 
Doxorubicin encapsulating AMA nanoparticles were successfully synthesized 
using a water-in-oil emulsion technique, and their size distribution was assessed by 
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dynamic light scattering. Particles were found to be under 200 nm diameter in general, 
with the peak size being 150 nm in diameter (see Figure 31). 
 
 
Figure 31: DOX-encapsulating nanoparticle size distribution was assessed using dynamic light 
scattering in PBS (pH 7.4, 37°C), and is presented in the above histogram by number. The peak size 
by number is located at 150 nm diameter, with a standard deviation of 19 nm. 
 
6.4.9. Mechanisms of drug release 
Drug release profiles for DOX-eluting chemotherapeutic patches and DOX-
encapsulated AMA nanoparticles were assessed over a 48 hour time period and presented 
in Figure 32 in micrograms DOX per milligram particles. During the initial 12 hours, the 
drug release expressed by the DOX-encapsulated AMA nanoparticles appears to be more 
rapid, with DOX-eluting sealant patches exhibiting delayed release of the 
chemotherapeutic drug. After 24 hours, little further drug is released, with no significant 
difference in the total amount of drug released by any test group after 24 or 48 hours 
respectively. 
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Figure 32: Drug release profiles (micrograms DOX per milligram particles) of DOX-loaded patches 
and nanoparticles over 48 hours at 37°C.  
 
 
6.4.11. Bioactivity of DOX-eluting chemotherapeutic patch 
The bioactivity of DOX-eluting adhesive patches, as compared to DOX-
encapsulating nanoparticles and non-loaded patches, was assessed using A549 cells, after 
24 hours exposure to the test materials and reported as viability in Figure 33. As can be 
seen, there was no decrease in viability observed after 24 hours exposure to non-loaded 
patch materials, whereas a significant decrease in cell viability was demonstrated by both 
the DOX-eluting patch formulations tested. Although DOX-encapsulating nanoparticles 
showed a decrease in cell viability, this difference was not significant. 
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Figure 33: A549 cell viability after 24 h exposure to non-loaded and DOX-loaded sealant patches and 
nanoparticles. No significant differences in viability were detected between control and non-loaded 
sealant patches. Viability is however decreased significantly for both DOX-loaded patch formulations 
tested. DOX-loaded nanoparticles show a slight reduction in viability but is not statistically 
significant at p=0.05. 
 
6.5. Discussion 
In a prior study, our laboratory investigated the sealant performance of AMA 
and AMA-DA blends applied in liquid form, to assess how varying the level of oxidation 
influenced the adhesion and burst pressure.14 This subsequent study further expands our 
work in functionalized alginate-based sealants by introducing a novel patch application 
system, which is intended for use as a lung tissue bandage.  
 
Pure AMA is inherently non-adhesive, and thus oxidation of the molecule was 
performed to take advantage of aldehyde-mediated adhesion to proteins commonly found 
on the tissue surface. Aldehyde modification of polymers has been shown to improve 
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adhesion to proteins found on or within biological tissues.12, 14, 17, 35-39 Using an oxidation 
reaction, it is possible to open the uronate residues found on the alginate backbone to 
form two functional aldehyde groups.  There is, however, a balance which must be 
achieved between the degree of oxidation/aldehyde-modification required to improve 
sealant adhesion, and the viscosity and mechanical performance of the material. As 
previously reported, and shown in Figure 24, the oxidation of alginate and AMA results 
in significant decreases in solution viscosity.14 This is due to a reduction in molecular 
weight or chain length of the polysaccharide molecules resulting from the deleterious 
oxidation reaction.13-14 A reduction in DOM can also be observed when increasing the 
level of oxidation, as quantified from the 1H-NMR spectra shown in Figure 23. For these 
reasons, the DOO was kept below 50% for the materials tested in this study. 
Additionally, the AMA-DA material was blended with non-oxidized AMA to partially 
recover the viscosity and mechanical performance of the sealant while still maintaining 
the important presence of aldehyde groups for adhesion. All the patch 
formulations/blends tested successfully photo-crosslink in under 5 minutes when 
hydrated and exposed to visible green light (525 nm) as confirmed by the plateauing 
storage moduli presented in Figure 25. 
 
Using a custom-made burst pressure testing device, a wide-range of sealant 
performance was observed between concentrations and formulations with several 
achieving burst pressures consistently above the physiological threshold of 12 in-H2O 
(Figure 28). At 3% and 4.5% w/v polymer concentration, variation between tests 
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remained excessively high, eliminating any margin of safety. Sealant patches fabricated 
from 6% w/v polymer solutions yielded improved results at reliably high burst pressures 
over 100 in-H2O on average.  AMA, when used alone, was lacking any aldehyde-mediate 
adhesion and thus was prone to delamination or adhesive failure (Table 3). In our study, 
we found that formulations prone to delamination also yielded the highest levels of 
variation between tests. Sealant patches containing AMA and AMA-DA at 1:1 or 1:2 
ratio fail almost exclusively via material failure, or rupture (Table 3), which is believed to 
be due to improved adhesion to the collagen substrate as well as weakened mechanical 
performance (Figure 24 & 5). 
 
Alginate-based materials are commonly utilized, and increasingly so, in 
biological and medical applications and are widely accepted as highly biocompatible. 
Indeed, mesothelial cells demonstrated no deleterious effects when cultured in the 
presence of alginate sealant patch materials over 24 hours, as confirmed by viability, 
cytotoxicity, apoptosis and mitochondrial activity assays (Figure 27). Inversely, when 
DOX-encapsulating AMA nanoparticles are incorporated into the adhesive patch and 
cultured alongside A549 human lung cancer cells, a significant decrease in cell viability 
is observed revealing potential applications for such a drug-eluting tissue adhesive patch. 
As the nanoparticles are made from the same AMA material as the sealant, the particles 
are seamlessly crosslinked within the hydrogel sealant. Drug release assays reveal 
delayed DOX release from the drug-eluting patches as compared to nanoparticles alone 
(Figure 32). This is because the drug, which has a relatively low solubility in aqueous 
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solutions, must not only diffuse through the particle but subsequently through the 
surrounding sealant hydrogel before ultimately diffusing into the surrounding 
supernatant. This bi-phasic diffusion delays drug release from the drug-eluting patch as 
compared to the nanoparticles.  Interestingly, though the DOX-encapsulating 
nanoparticles release the drug more rapidly than DOX-eluting patches, they appear less 
effective in killing cancer cells over a 24 hour period (Figure 33). Due to the small size of 
these particles, approximately 150 nm in diameter, and prior research performed using 
similar particles, it is thought that many of the particles within the culture are rapidly 
internalized by A549 cells.15 In prior studies, efficacy of DOX-encapsulating particles in 
clearing cancer cell populations improved over a 5 day period, and it is thought that once 
internalized the particle and drug may be temporarily trapped within an endosome and 
not immediately available to act on the cell nuclei and DNA. The pH within an endosome 
can also vary significantly from that of the cell culture media, also influencing drug 
release. Decreasing pH can induce protonation of the carboxylate side groups on the 
alginate backbone, causing hydrogen bonding to occur and an increase in viscosity, 
ultimately slowing diffusion processes further in internalized nanoparticles.8 
 
6.6. Conclusions 
Dry sealant patches were successfully designed and fabricated including all 
necessary reactants for photocrosslinking using visible green light. Methacrylated 
alginates were found to require moderate aldehyde modification to improve adhesive 
properties of the hydrogel material. Blending of non-oxidized material with oxidized 
(aldehyde modified) alginates yields patches with improved burst pressure performance, 
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and decreased delamination as compared with pure AMA. Drug-eluting adhesive patches 
also show efficacy when loaded with DOX-encapsulating nanoparticles and cultured in 
the presence of A549 human lung cancer cells over a 24 hour period, suggesting 
diversified medical applications. 
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS  
 
 
7.1. Summary of Work and Concluding Remarks 
The work performed and presented in this dissertation was primarily motivated 
by the clinical need for biocompatible and bioadhesive materials with tunable mechanical 
properties. To accomplish this, I began by developing a novel anhydrous methacrylation 
chemistry, which can be broadly applied to many polysaccharides including hyaluronan 
and sodium alginate. This work advances prior research utilizing methacrylated 
polysaccharides by demonstrating the ability to control the degree of crosslinking through 
calculated adjustment of reactants, thus modulating the mechanical properties of the 
resulting hydrogel, making these materials broadly applicable to many tissue engineering 
and regenerative medical purposes. Additionally, we show the ability to use visible green 
light for covalent photo-crosslinking of methacrylated polysaccharides through the use of 
an Eosin Y-based photoinitiator system, and yet still achieve mechanical properties 
equivalent to or exceeding those achieved using cytotoxic ultraviolet light initiated 
systems. 
 
Subsequently, we utilize methacrylated alginate to synthesize a novel injectable 
tissue sealant capable of in situ tissue repair using visible green light initiated photo-
crosslinking. In this work, we further functionalized the polysaccharide molecule through 
an oxidation reaction which opens the uronate residues found on the carbohydrate 
backbone to form two aldehyde groups per repeat unit. These aldehyde groups were 
shown to influence the adhesion of our hydrogel material to extracellular matrix proteins 
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found on tissue surfaces, such as collagen, through imine bonding. By modulating the 
degree of oxidation, we varied the number of aldehyde groups available for adhesion to 
proteins. We also found that the oxidation of polysaccharide molecules can reduce 
molecular chain length and further influence the mechanical properties of the adhesive 
material. This work builds on the literature by demonstrating the ability to blend 
oxidized-methacrylated alginates with methacrylated alginates to improve sealant 
performance as confirmed by burst pressure testing. 
 
Methacrylated- and aldehyde-modified alginates were once again utilized in the 
design and fabrication of pulmonary sealant patches, introducing a novel mechanism for 
sealant application. The adhesive polysaccharide-based patches were formed using an 
injection molding technique, with subsequent lyophilization, to produce dry sheets of 
polymer material which can be applied to damaged tissues, hydrated and crosslinked to 
seal perforations and leaks. The performance and adhesion of these novel adhesive 
patches was assessed using a custom burst pressure testing device, and were shown to 
vastly exceed the performance of the aforementioned liquid sealant. The sealant materials 
were found not to be cytotoxic or induce apoptosis in human mesothelial cells, showing 
promise for the use of such a patch system on pulmonary tissues. 
 
Another aim of this research was to provide a mechanism of controlled 
intracellular drug delivery in the treatment of disease and/or tissue engineering and 
regenerative medicine applications. Methacrylated alginate was blended with a model 
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drug, in this case doxorubicin hydrochloride, and subsequently formed into sub-micron 
and nano-sized particles through a water-in-oil emulsion technique. The 
chemotherapeutic drug was encapsulated within the individual particles, and trapped via 
covalent photo-crosslinking techniques. The resulting particles were shown to effectively 
deliver bioactive drug, intracellularly, inducing cell death in human lung cancer cells. It is 
hoped that by taking advantage of cell internalization pathways, improvements in the 
efficacy of anti-cancer therapies can be made while simultaneously reducing effective 
dosages and systemic side effects. 
 
By combining the aforementioned doxorubicin encapsulating alginate 
nanoparticles within my novel adhesive alginate sealant patch, I have additionally shown 
the ability to effectively deliver chemotherapeutics to human lung cancer cells. These 
drug-loaded adhesive patches could be applied to many tissues internally, and remain in 
place, while allowing for local drug release. The impact of this work, although 
preliminary, could be broad due to the frequent need/want to administer therapeutic drugs 
in site-specific manner. The benefits to such a method of administration could translate to 
lower effective doses of drug, and a reduction in systemic side effects. 
 
7.2. Future Directions 
There are several directions I foresee this promising and exciting work 
proceeding in the future. With our in vitro burst pressure model showing sufficient 
performance, well exceeding physiological pressures, the most obvious next step to be 
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undertaken is the use of these adhesive hydrogels in vivo to seal lung defects. Indeed, 
this work has already been initiated in our laboratory in collaboration with researchers 
at the Larner College of Medicine at the University of Vermont. Having already 
performed several proof-of-concept tests using excised murine lungs in 2014, we have 
since begun preparation for in vivo testing of our novel adhesive sealant hydrogels. We 
plan to use the Scireq® FlexiVent™ system to monitor lung function and respiratory 
mechanics in healthy mouse lungs, then repeat measurements after perforating the lung 
with a small incision, and again after sealing the wound with our novel alginate sealant 
hydrogels. Relevant IACUC, surgical and experimental protocols have been developed, 
validated and approved for our future animal studies. We hope that these future 
experiments will prove to be successful, so that we may continue our ongoing 
technology commercialization efforts. 
 
Additionally, having shown the ability to successfully deliver therapeutic 
molecules using the adhesive alginate hydrogels, we hope to begin an investigation into 
the delivery of growth factors to aid in the healing of damaged and diseased lung 
tissues. Recently we have shown that intracellular delivery of fibroblast growth factor-2 
(FGF-2) can selectively induce cell death in A549 lung cancer cells, yet appears to have 
no effect on normal lung epithelial cells. It has also been shown that FGF-2 can aid in 
tissue and would healing. Indeed, this very work was the subject of a recently issued 
NIH R01 awarded to our laboratory and will be a primary focus of the Oldinski 
laboratory over the upcoming years. 
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APPENDIX I: STANDARD OPERATING PROCEDURE: ALGINATE 
METHACRYLATION WITH METHACRYLIC ANHYDRIDE IN WATER 
Author: Spencer L. Fenn, Rachael A. Oldinski, Patrick Charron 
 
MATERIALS:  
• Alginate (Alg) (FMC BioPolymer) 
• Methacrylic anhydride (MA) (Simga-Aldrich) 
• 2N sodium hydroxide (NaOH) (Sigma-Aldrich) 
 
METHODS: 
 
a) Add 1 gram Alg to 100 mL DI water to form a 1% (w/v) solution. (Use 0.25g in 
25 mL for quarter batch) 
b) Add 8.46 mL MA (2.11 mL for quarter batch) to the Alg solution to form a 20-
fold molar excess*. Adjust the pH of the solution to 8.5 with 2N NaOH. Stir the 
solution overnight (>12 h) at room temperature in a round bottom flask. 
Periodically adjust the pH with 2N NaOH as necessary. 
c) Adjust the pH of the final solution to pH 7.0 and dialyze with DI water for 3 days, 
changing solution every 6-8 hours. 
d) Freeze the solution in the -80 °C freezer in a lyophilizer flask and lyophilize. 
 
*This method assumes 1 mol MA = 1 mol Alg (repeat unit) 
Alg MW: 352.24 g/mol 
 
REFERENCE: 
1. Skardal, A. et al. “Photocrosslinkable Hyaluronan-Gelatin Hydrogels for Two-
Step Bioprinting”, Tissue Engineering: Part A. v.16, n.8, pp2675-2685, 2010. 
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APPENDIX II: STANDARD OPERATING PROCEDURE: AA-CTA SYNTHESIS 
Author: Spencer L. Fenn 
 
MATERIALS:  
• Alginate (FMC BioPolymer) 
• Hexadecyltrimethylammonium bromide (CTAB - Sigma Aldrich) 
• Deionised water 
 
METHODS: 
 
1) Make 1% w/v polymer solution in deionized water and set aside for later use. 
 
2) In a separate vessel, make an equal volume of 4% w/v CTAB in water solution, may 
need to heat slightly until solution goes clear.  
 
3) Mix solutions. 
 
4) After 24 hours centrifuge or filter off supernatant (or simply put solution in large 
beaker, cover and allow to sit in fume hood, polymer will settle and supernatant can 
be removed easier). Rinse several times with 70% ethanol in water. 
 
5) Freeze at -80°C and lyophilize. 
 
REFERENCE: 
 
1. Oudshoorn, M.H.M. et al. “Synthesis of methacrylated hyaluronic acid with 
tailored degree of substitution”, Polymer, v.48, pp1915-1920, 2007. 
2. Moller, L. et al. “Preparation and evaluation of hydrogel-composites from 
methacrylated hyaluronic acid, alginate, and gelatin for tissue engineering”, Int J 
Artif Organs, v.34, n.2, pp93-102, 2011. 
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APPENDIX III: STANDARD OPERATING PROCEDURE: AA-DTA SYNTHESIS 
Author: Spencer L. Fenn 
 
MATERIALS:  
• Alginate (FMC BioPolymer) 
• Dodecyltrimethylammonium bromide (DTAB) 
• Deionised water 
 
METHODS: 
 
6) Make 1% w/v polymer solution in deionized water and set aside for later use. 
 
7) In a separate vessel, make an equal volume of 2-3% w/v DTAB in water solution, 
may need to heat slightly until solution goes clear.  
 
8) Gradually mix solutions together. Precipitate should immediately begin to form. 
 
9) After 2-4 hours centrifuge or filter off supernatant (or simply put solution in large 
beaker, cover and allow to sit in fume hood, polymer will settle and supernatant can 
be removed easier). Rinse several times with DI water.  
 
10) Freeze at -80°C and lyophilize. 
 
REFERENCE: 
 
1) Oudshoorn, M.H.M. et al. “Synthesis of methacrylated hyaluronic acid with tailored 
degree of substitution”, Polymer, v.48, pp1915-1920, 2007. 
2) Moller, L. et al. “Preparation and evaluation of hydrogel-composites from 
methacrylated hyaluronic acid, alginate, and gelatin for tissue engineering”, Int J Artif 
Organs, v.34, n.2, pp93-102, 2011. 
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APPENDIX IV: STANDARD OPERATING PROCEDURE: 
METHACRYLATION OF ALGINATE WITH METHACRYLIC ANHYDRIDE IN 
DMSO 
Author: Spencer L. Fenn, Patrick N. Charron 
 
MATERIALS:  
• AA-DTA (See AA-DTA synthesis SOP) 
• Anhydrous dimethyl sulfoxide (DMSO) (Sigma-Aldrich) 
• 4-Dimethylaminopyridine (DMAP: MW=122.17g/mol) (Sigma Aldrich) 
• Methacrylic anhydride (MA: MW=154.16g/mol; density=1.035g/mL) (Sigma-
Aldrich) 
• HCl Solution 
• Sodium Phosphate Dibasic (Fisher) 
METHODS: 
 
3) Add 25 mL DMSO to 0.25 g AA-DTA (See AA-DTA synthesis SOP) under nitrogen 
gas flow in a 250 mL round bottom flask to make a 1% AA-DMSO solution. 
e) Heat may need to be applied via mineral oil bath up to 100°C until in solution. 
f) Allow DMSO solution to cool to room temperature before adding DMAP and 
MA 
 
2) Add DMAP using 1:2 molar ratio, DMAP:AA-DTA 
a) gDMAP
molg
molgg 0263.0
2
1
/682.580
/17.12225.0 =••  
 
3) Add enough methacrylic anhydride to equal two times the molar requirements for 
100% modification (0.464 mL) under nitrogen atmosphere and allow to stir 
overnight. 
a) mL
g
mLg
molg
molgg 128.0
035.1
11327.08
/682.580
/16.15425.0 =•=••  
b) The multiplication factor of 8 allows for 100% excess to insure 100% 
modification. Alter for lower degrees of modification 
 
4) Add HCl to molar equivalent of DMAP used. 
 
5) Dialyze against DI water for 3 days to remove DMSO and excess MA and DMAP, 
dialyze against sodium phosphate dibasic until clear, and then several days in DI 
water to remove excess sodium ions.  
6) Freeze at -80°C and lyophilize. 
7) See chemistry in schematic form on following page. 
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Appendix IV Continued: Anhydrous Methacrylation Chemistry Schematic 
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APPENDIX V: STANDARD OPERATING PROCEDURE: HYALURONAN  
METHACRYLATION IN WATER WITH GLYCIDYL METHACRYLATE 
Author: Spencer L. Fenn, Rachael A. Oldinski 
 
MATERIALS:  
• Hyaluronan (HA) (Lifecore Biomedical) 
• Phosphate buffered saline (PBS, pH 7.4) (Amresco) 
• Dimethylformamide (DMF) (Sigma-Aldrich D119) 
• Glycidyl methacrylate (GMA) (Sigma-Aldrich 779342) 
• Triethylamine (TEA) (Sigma-Aldrich T0886) 
• Ethanol or Acetone 
 
METHODS: 
 
11) Add 0.25 g HA to 50 mL PBS solution and 16.75 mL DMF. 
12) Add 3.325 g GMA (3.2 mL) and 1.675 g of TEA (2.3 mL) to the HA solution. Stir at 
room temperature for 10 days. 
13) The reaction solution was precipitated with 180-200 mL ethanol or a 20-fold volume 
excess of acetone.   
14) The reaction solution was filtered (or centrifuged), and dialyzed against DI water for 
3 days, exchanging water every 6-8 hours.  
15) The solution was then frozen at -80 °C and lyophilized. Final mass taken for yield 
calculations. 
  
REFERENCE: 
Bencherif, S.A. et al. “Influence of the degree of methacrylation on hyaluronic acid 
hydrogels properties”, Biomaterials, v.29, pp1739-1749, 2008. 
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APPENDIX VI: STANDARD OPERATING PROCEDURE: UV PHOTO-
CROSSLINKING OF METHACRYLATED BIO-POLYMERS 
Author: Spencer L. Fenn 
 
MATERIALS:  
• Methacrylated Hyaluronan (HA-MA) or Alginate (AA-MA) 
• Irgacure D2959 (Ciba), or other photoinitiator. 
• De-ionized Water 
 
METHODS: 
 
NOTE: The majority of this protocol should be performed with minimal light exposure to 
prevent premature crosslinking, or deactivation of photoinitiator. 
 
16) A 0.05% (w/v) solution of Irgacure D2959 in De-ionized water was prepared with 
minimal light exposure due to photosensitivity of the photoinitiator. As the 
photoinitiator is not readily soluble in water at room temperature, sonication may be 
used to facilitate this process (15 min). 
17) A 2-4% (w/v) solution of HA-MA/AA-MA in the aforementioned solution was mixed 
until fully in solution. 
18) Polymer solution was injected into required mold ensuring UV light was able to pass 
through solution fully, ie, using glass. 
19) Using UV lamp, the mold and polymer solution were exposed to UV light for 
designated time points (i.e. 1, 5, 10, 15 min) which may alter degree of crosslinking. 
 
REFERENCE: 
Aleksander Skardal et al., “Photocrosslinkable Hyaluronan-Gelatin Hydrogels for Two-
Step Bioprinting.,” Tissue Engineering. Part A 16, no. 8 (August 1, 2010): 2675–2685. 
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APPENDIX VII: STANDARD OPERATING PROCEDURE: EOSIN Y 
CROSSLINKING HA-MA OR AA-MA 
Author: Spencer L. Fenn 
 
MATERIALS:  
• Methacrylated Alginate or Hyaluronan (previously synthesized in lab) 
• Eosin Y (Acros Organics MW: 691.85 g/mol) 
• 1-vinyl-2-pyrrolidinone (Sigma, V3409, MW: 111.14 g/mol, ρ: 1.04 g/mL) 
• Triethanolamine (Sigma, 90279, MW: 149.19 g/mol, ρ: 1.124 g/mL ) 
METHODS: 
 
CAUTION: All steps prior to crosslinking should be performed in a darkened room 
with no visible green light sources. All solutions should be stored out of light, 
preferably in refrigeration. 
 
1. Prepare stock crosslinking solutions (Nettles, Vail, Morgan, & Grinstaff, 2004): 
a. 2 mL methacrylated polymer solution in DI water (typically 1-4%). 
b.  0.5% eosin Y (photosensitizer, EY) in 1-vinyl-2-pyrrolidinone (catalyst, 
1VP) 
c. 5M triethanolamine (initiator, TEOA) in DI water. 
2. Add 5 µL of the EY/1VP solution to the 2 mL polymer solution and mix. 
3. Add 50 µL of the TEOA solution to the polymer solution and mix thoroughly 
4. Fill mold with polymer crosslinking solution. 
a. Molds should be fully translucent to allow for full crosslinking of gels. 
5. Expose mold to visible green light of wavelength 510 nm for 2-6 minutes to 
crosslink hydrogel(Bahney, Lujan, & Hsu, 2011). 
 
REFERENCE: 
Bahney, C., Lujan, T., & Hsu, C (2011). Visible light photoinitiation of mesenchymal 
stem cell-laden bioresponsive hydrogels. European Cells and, 1-13. Retrieved from 
http://www.biomechresearch.org/PDF/Visible%20light%20photoinitiation.pdf 
 
Nettles, D., Vail, T., Morgan, M., & Grinstaff, M (2004). Photocrosslinkable hyaluronan 
as a scaffold for articular cartilage repair. Annals of biomedical, 1-7. Retrieved from 
http://link.springer.com/article/10.1023/B%3AABME.0000017552.65260.94 
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APPENDIX VIII: STANDARD OPERATING PROCEDURE: IN VITRO 
CYTOTOXICITY ASSAY, MTT BASED  
Author: Spencer L. Fenn (Modified from Sigma Protocol) 
 
 
MATERIALS:  
• 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, MTT (Sigma: 
M5655) 
• Dimethyl Sulfoxide (Bioreagent Grade) 
• Cell Culture Media or Salt Solution WITHOUT Phenol Red (Phenol red has 
absorbance at 570 nm, contributing to increased background, and decreased test 
sensitivity) 
METHODS: 
 
Note: MTT is light sensitive, it is best to keep lights dimmed as much as possible. Do not 
leave solutions exposed to light for extended periods of time. 
1) Prepare MTT Solution. Refrigerate/freeze until use. 
a. Add MTT to PBS or balanced salt solution (without phenol red and 
serum) at 5 mg/mL concentration. Mix until dissolved. Usually no 
more than 3 mL will be required. 
b. Excess solution can be stored frozen for up to 6 months. 
2) Seed well plate with cells, incubate allowing cells to adhere and expand for at 
least 24 hours (or to desired confluency). Make sure to seed wells for positive 
control. Also leave several wells empty (with just media) for “blank” 
adjustment if desired.  
a. 48 well plates are best for MTT, avoid using anything with less surface 
area. 
b. Transwell plates can also be used when testing cytotoxicity of solid 
materials/scaffolds. 
c. If possible, use media without phenol red. If unavailable, media with 
phenol red can be utilized during initial cell expansion and culture 
with test material, but remove and replace with a balanced salt solution 
(PBS, etc) without phenol red when you add MTT solution. Expect 
decreased sensitivity in this case. 
3) Add test solution/material and allow to culture in incubator for 24 hours. 
4) Add previously prepared MTT solution at 10% of the media volume to each 
well, including controls/blanks. 
a. Incubate for 2-4 hours. Usually 2 hours is sufficient, you should see 
dark purple formazan crystals appear as the MTT is metabolized by 
cells. If your cell population is lower or their metabolic rate is slower, 
you may need to culture for up to 4 hours. 
5) Carefully aspirate all media/MTT solution from each well. 
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a. Try not to remove any purple formazan crystals from the wells as this 
will increase your variation between wells. 
b.  If concerned about accidentally removing crystals during aspiration, 
you can leave a small (known) amount of MTT/Media/PBS in each 
well, but this will increase background and reduce sensitivity. 
6) Add DMSO to each well, 150-200 uL typically if using a 48 well plate 
(consider if you are making duplicates or triplicates. You can add up to 
original media volume if needed). The DMSO will help dissolve the formazan 
crystals for detection on the plate reader. 
a. Using an incubator shaker (preferred, as doesn’t create bubbles) or 
gently pipetting up and down can aid in dissolving the crystals. 
b. The solutions should turn varying degrees of purple. The deeper the 
purple, the less cytotoxicity experienced. Your blank wells should 
remain clear. 
7) Take aliquots (typically 50-100 uL, just be consistent throughout) from each 
test well and place in a 96 well plate (untreated). 
a. Usually duplicates/triplicates will be taken from each test well. In other 
words, if you started with an n=3, you should end up with 6 or 9 wells 
for plate reading. 
8) Read absorbance at 540 nm and 690 nm (background) using plate reader. 
a. Subtract background at 690 nm from the absorbance at 540 nm to 
obtain raw absorbance of each well. 
b. Additionally, you can perform Blank Adjustment using your blank 
wells if desired (not always necessary, but can increase sensitivity) 
c. Data can be normalized to your positive control wells. 
 
 
References: 
Wang, H.; Wang, F.; Tao, X.; Cheng, H., Ammonia-Containing Dimethyl Sulfoxide: 
An Improved Solvent for the Dissolution of Formazan Crystals in the 3-(4,5-
Dimethylthiazol-2-Yl)-2,5-Diphenyl Tetrazolium Bromide (Mtt) Assay. Anal. 
Biochem. 2012, 421 (1), 324-6. 
 
Twentyman, P. R.; Luscombe, M., A Study of Some Variables in a Tetrazolium Dye 
(Mtt) Based Assay for Cell Growth and Chemosensitivity. Br. J. Cancer 1987, 56 
(3), 279-285. 
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APPENDIX IX: STANDARD OPERATING PROCEDURE: PARTIAL 
OXIDATION OF ALGINATE 
Author: Patrick Charron, Spencer L. Fenn 
 
Materials: 
• Alginate (FMC BioPolymer) 
• Sodium Periodate, NaIO4 (Sigma Aldrich) 
• Deionised water 
 
Methods: 
1) Prepare 1-2% w/v polymer solution in deionized water 
2) In separate vessel, prepare 2-5% w/v NaIO4 solution in deionized water for 
desired degree of oxidation 
a. Theoretical DOO equivalent to Alginate:NaIO4 ratio 
e.g. 10 DOOà 1 g Alginate:0.1g NaIO4 
3) Mix NaIO4 solution into alginate solution and allow to stir for 24 hrs at room 
temperature in dark space 
4) Dialyze against deionized water for 3 days 
5) Freeze at -80°C and lyophilize 
Note: Oxidation reaction can be stopped by addition of molar equivalent of ethylene 
glycol to NaIO4 
 
Reference: 
1) Bouhadir, Kamal H., et al. "Degradation of partially oxidized alginate and its 
potential application for tissue engineering." Biotechnology progress 17.5 (2001): 
945-950. 
2) Jeon, Oju, et al. "The effect of oxidation on the degradation of photocrosslinkable 
alginate hydrogels." Biomaterials 33.13 (2012): 3503-3514. 
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APPENDIX X: STANDARD OPERATING PROCEDURE: PREPARATION OF 
CROSSLINKABLE AA-MA/HA-MA FILM PATCHES VIA SPIN COATING 
Author: Spencer L. Fenn 
 
 
MATERIALS:  
• Spin Coater 
• Dessicator/Lyophilizer 
• Razor Blade 
• Methacrylated Alginate or Hyaluronan 
• Photoinitiators 
o Irgacure D2959 
OR 
o Eosin Y (photosensitizer, Acros Organics MW: 691.85 g/mol) 
o 1-vinyl-2-pyrrolidinone (catalyst, Sigma, V3409, MW: 111.14 g/mol, ρ: 
1.04 g/mL) 
o Triethanolamine (initiator, Sigma, 90279, MW: 149.19 g/mol, ρ: 1.124 
g/mL ) 
METHODS: 
 
9) Prepare polymer solutions (higher concentration=denser/thicker films) with 
photoinitiators. Caution: Take care not to expose solutions to activating 
wavelengths, i.e. UV and Green Light (510nm). Please note that even 
fluorescent lighting will trigger gelation of eosin Y based solutions. It may be 
best to use mixing syringes to get fully homogenous solutions. 
a.) 0.05% Irgacure D2959 in water 
OR 
b.) 0.00125% (w/v) eosin Y (photosensitizer), 125mM triethanolamine 
(TEOA, initiator), and 19mM 1-vinyl-2-pyrrolidinone (1VP, 
catalyst). 
10) Using spin coater, coat a glass slide with the polymer solution. Film thickness 
can be adjusted by altering speed and length of time. Suggested settings : 1500 
rpm for 5-10 seconds. 
11) Take coated slide and lay flat in vacuum oven/dessicator (in complete 
darkness, using vacuum if possible and low heat) until dry OR lay flat in -80C 
freezer and subsequently lyophilize, again ensuring to keep sample in 
complete darkness to prevent premature gelation. (Possible pitfall with 
lyophilization: when the polymer solution freezes, ice crystals form 
throughout and thus the final lyophilized film is highly porous. If this 
becomes an issue, rely on vacuum desiccation.) 
12) Once dry, films can be removed from slide using razor blade. 
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13) To use films, simply cut to size, and stick to wet tissue. Allow film to hydrate 
by absorbing surrounding water, and then expose the patch to its activation 
light source, i.e. UV or green light for 10 min. 
 
 
 
REFERENCE: 
Park, Y., Tirelli, N., & Hubbell, J (2003). Photopolymerized hyaluronic acid-based 
hydrogels and interpenetrating networks. Biomaterials, 24(6), 893-900. 
doi:10.1016/S0142-9612(02)00420-9 
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APPENDIX XI : INTERDISCIPLINARY RESEARCH WORKSHOP REPORT 
 
Spencer L. Fenn 
4th-year Ph.D. Candidate in Bioengineering, University of Vermont 
Title:   Intracellular Delivery of Bioactive Chemotherapeutic Using Dual-
Crosslinked Alginate Sub-Microparticles 
Presented to the Vermont Lung Center 
November 10th, 2015 
 
In follow-up to the talk titled “Intracellular Delivery of Bioactive 
Chemotherapeutic Using Dual-Crosslinked Alginate Sub-Microparticles” presented to the 
Vermont Lung Center on November 10th, this report is intended to summarize the 
multidisciplinary aspects of this work as discussed during the subsequent 
Interdisciplinary Research Workshop (IRW). Present at the IRW were UVM faculty 
members, post-doctoral fellows and student trainees specializing in materials science, 
engineering, bioengineering, pulmonary medicine and cellular & molecular biology.  
In this presentation, the synthesis of novel dual-crosslinked sub-microparticles 
was described as well as their application for use as intracellular chemotherapeutic 
delivery vehicles in lung cancer cells. This work bridges several fields including 
chemistry and materials science, engineering, pharmacology, cell biology, and pulmonary 
medicine. The primary hypotheses of the presented work were,  
1) chemotherapeutic release profiles can be modulated or extended through secondary 
crosslinking of drug-encapsulated alginate sub-microparticles, and 2) intracellular 
delivery of bioactive chemotherapeutic to lung cancer cells will result in increased cell 
death and cytotoxicity at lower drug dosages as compared to extracellularly delivered 
chemotherapeutic dosed in cell growth media. The main topics of discussion for this talk 
included an introduction to the material used, sodium alginate, as well as the chemical 
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modification required to allow for covalent crosslinking; the fabrication of doxorubicin 
encapsulated single and dual-crosslinked alginate sub-microparticles; characterization of 
these particles by size, shape, surface charge and drug-release profiles; and lastly an 
investigation into particle internalization or cell uptake, and the cytotoxicity/bioactivity 
on human lung cancer cells (A549, epithelial carcinoma). 
The first disciplines discussed during this presentation were that of materials 
science and chemistry. Alginate is a long-chain anionic polysaccharide derived from 
brown algae made up of guluronate and mannuronate sugar residues. The primary 
motivations for utilizing this material are its inherent biocompatibility, chemically 
modifiable hydroxyl and carboxyl side-groups (for material functionalization), as well is 
its sustainable source. Alginate is also capable of reversible ionic cross-linking between 
guluronate residues in adjacent polysaccharide chains in the presence of calcium ions. 
Additionally, alginate can be covalently crosslinked by means of chemical 
methacrylation of hydroxyl groups on the molecule repeat unit, forming methacrylate 
alginate (Alg-MA). Methacrylation allows for free-radical initiated crosslinking between 
polysaccharide chains, often using ultraviolet or visible light sensitive photoinitiators. 
During this presentation, a brief overview of a novel anhydrous methacrylation chemistry 
was described. The degree of methacrylation influences the degree of crosslinking with 
more methacrylate groups equating to a tighter network structure. These two means of 
crosslinking, both ionic and covalent, can be utilized alone or in combination to form 
single or dual-linked hydrogels.  
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Following the discussion of chemistry, the engineering and synthesis of 
doxorubicin encapsulating, single and dual-crosslinked sub-microspheres and the 
subsequent assessment of physical properties were discussed. Aqueous solutions of Alg-
MA and doxorubicin were blended, and added dropwise into oil/surfactant stirring 
rotationally at high speed forming a water-in-oil emulsion. As the solution stirs, non-
crosslinked droplets of Alg-MA are broken into increasingly smaller and smaller 
droplets. Photocrosslinking is then performed by exposing the emulsion to visible or UV 
light for ten minutes, covalently crosslinking the droplets to form sub-micron size 
doxorubicin encapsulating particles. Some particles were then dual-crosslinked by the 
addition of an aqueous calcium chloride solution, forming a tighter network structure 
with additional ionic bonds between adjacent guluronate sugar residues. The particle size 
was quantified using dynamic light scattering, and shape by scanning electron 
microscopy. The particles were found to range from approximately 100-600 nanometers, 
a size range which is typically appropriate for cellular internalization. As cellular uptake 
is also influenced by particle surface charge, with more neutral particles providing 
enhanced internalization, the zeta-potential of the particles was also quantified with all 
particles found to be negative in charge ranging from -20 to -37 mV.  
A discussion of drug release was then provided, showing that dual-crosslinked 
particles do indeed exhibit reduced and extended drug release as compared to single 
crosslinked particles, confirming the first hypothesis. The release profiles for the dual-
crosslinked particles were found to release significantly less drug overall, which led us to 
believe that there may be reduced encapsulation efficiency in dual-crosslinking particles 
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due to the addition of aqueous calcium chloride solution to the emulsion which is capable 
of washing away drug. Several suggestions were provided by audience members to 
enhance the quantification and analysis of the data, such as integration of the release 
curves to determine encapsulation efficiency and show differences between each 
crosslinking type as well as developing models to elucidate the mechanisms dictating 
release from the hydrogel material. It was agreed that further investigation into the 
already recorded data could prove both interesting and valuable. 
Internalization of the particles was then discussed in depth, with the audience 
asking many questions relating to verification of cellular uptake. At the time of the 
presentation, solely flow cytometry had been used to show increased fluorescent intensity 
of A549 cells cultured in the presence of fluorochrome labelled particles. Several 
audience members hypothesized that the particles could simply be aggregating just 
outside of the cell membrane, increasing the fluorescence reading. It was suggested that 
further analysis would be required to confirm cellular internalization, such as confocal 
microscopy using multiple stains to localize particles within the cell membrane, or using 
endosomal markers to show particles within endosomes. Since that time, we have 
investigated A549 particle internalization further and performed confocal microscopy at 
various time-points showing the gradual internalization process underwent by the 
particles. We now feel reasonably confident that the particles are indeed readily 
internalized by this cell line. Also discussed at the presentation and subsequent IRW was 
how surface charge relates to internalization. Upon investigation of the percentage of 
cells tested positive for particle uptake, it was found that the particles exhibiting the most 
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neutral charge (UV crosslinked) were far more readily internalized by the A549 cells, 
with over 90% testing positive as compared to only 60% testing positive for visible-light 
crosslinked particles. Initially it was though these differences could have been attributed 
to size of particles, but after consideration and discussion it was established that particle 
surface charge had a greater influence on cellular uptake than originally thought. Also 
suggested during the IRW was to investigate how particle uptake occurs and what 
happens to the particle upon internalization.  
Lastly, the bioactivity/toxicity of the doxorubicin encapsulating particles over a 5 
day period was described as compared to extracellularly delivered drug in media at 
various concentrations. The data presented showed decreased metabolic activity as 
particle/drug dosage increase as expected. When compared, day one results showed 
enhanced cell cytotoxicity using alginate particles despite theoretically delivering 
significantly reduced dosages of drug overall. It was suggested that the reduced dosage 
may still provide increased efficacy when delivered intracellularly, directly within the 
cell. Although not all of the particles performed as well over the longer time periods of 3 
and 5 days, it is thought that these differences are more likely related to variances in 
initial drug encapsulation and reduced drug release as time progresses. It was also 
proposed that there may be fewer particles available for internalization at later time 
points. As advised by attendees previously, elucidation and model development of the 
drug release mechanisms may provide further insight into why efficacy decreases as time 
progresses and varies between the single and dual-crosslinked particles. 
 204 
 
In conclusion, the discussion during my presentation and in the following 
Interdisciplinary Research Workshop provided me with invaluable insight from experts 
within and outside my immediate research field. Many questions raised were not things 
that I, nor my supervisor, had initially considered and thus an outsider’s perspective was 
extremely appreciated and well received. The encouragement to look deeper and further 
analyze my data will also help to improve my overall understanding of my work and 
enhance the conclusions drawn. I found the workshop particularly beneficial as it allowed 
me to think more critically to develop and enhance my work prior to submission of a 
manuscript and public presentation to a large society conference later this year. 
 205 
 
APPENDIX XII: MET-5A HOMO SAPIENS MESOTHELIUM CELL CULTURE 
Author: Adapted from ATCC Protocol by Spencer L. Fenn 
 
MATERIALS:  
 
Complete Growth Medium 
• Medium 199 (Sigma Catalog No. M4530) 
• 400 nM Hydrocortisone (Sigma Catalog No. H0888, MW: 362.46) 
• 870 nM Bovine Insulin (Sigma Catalog No. I1882 or I6634, MW: 5733.49) 
• 3.87 µg/L Selenious acid (Aldrich Catalog No. 211176) 
• Trace elements B 1000X solution at 1000 dilution. (Mediatech/Corning Catalog 
No. 99-175)  
• 20 mM HEPES (Life Technologies Catalog No. 15630) 
• 10% Fetal Bovine Serum (ATCC Catalog No. 30-2020, not heat-inactivated) 
• *3.3 nM Epidermal Growth Factor (EGF) (Corning Catalog No. 354001, MW: 6 
kDa, 6000 g/mole) *ADD AFTER FILTERING 
Note: All values listed above are final concentration. All components must be filter 
sterilized, except the EGF, which may be retained in filter membrane and thus can 
be added separately.  
Additional Materials Required 
• 0.25% (w/v) Trypsin- 0.53 mM EDTA solution 
• Dimethyl Sulfoxide (Sigma Cat. No. D2650) 
 
METHODS: 
 
Subculturing 
Volumes are given for a T75flask.  
1) Remove and discard culture medium. 
2) Rinse the cell layer with 1-2 mL Trypsin-EDTA solution to remove all traces of 
serum containing trypsin inhibitor. 
3) Add 3.0 mL of Trypsin-EDTA solution to flask and incubate for 5-10 minutes at 
37°C, or until cells release from flask and are freely floating. Do not tap or 
shake to release cells as this may cause aggregation to occur. 
4) Add 6.0 to 8.0 mL of complete growth medium and mix by  gently pipetting. 
5) Transfer cell solution to centrifuge tube and spin, 125 x g for 5 to 10 minutes. 
Discarding supernatant, resuspend cells in fresh growth medium. Add 
appropriate aliquots of cell suspension to new culture vessels. 
6) Incubate cultures at 37°C. 
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended 
Medium Renewal: Every 2 to 3 days 
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Note: Heavy floating debris is normal to observe, as are floating but viable cells. 
Please retain floating cells (using centrifugation) and return to flask for the first week 
after thawing cells, to allow for recovery from cryopreservation. The floating cells 
will attach when the culture has completely recovered from cryopreservation.   
 
 
Cryopreservation  
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO 
Storage temperature: liquid nitrogen vapor phase 
 
 
REFERENCES: 
1. Reddel, R. R.; Yang, K.; Rhim, J. S.; Brash, D.; Su, R. T.; Lechner, J. F.; Gerwin, 
B. I.; Harris, C. C.; Amstad, P., Immortalized Human Bronchial Epitherial 
Mesothelial Cell Lines. Google Patents: 1989. 
 
2. https://www.atcc.org/products/all/CRL-9444.aspx#culturemethod 
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APPENDIX XIII: VERMONT LUNG CENTER, T32 MULTIDISCIPLINARY 
TRAINING IN LUNG BIOLOGY FELLOWSHIP APPLICATION 
 
Research Plan 
 
Injury to the connective tissue that lines the lung, the pleura, or to the lung itself can occur from many 
causes including trauma, as well as underlying lung diseases or lung cancers. Bronchopleural fistulas, 
malignant pleural effusions, and traumatic or ventilator-induced pleural injuries are a continuing source of 
morbidity, mortality, and increased health care expenditures.  There are currently only limited means of 
patching significant injuries to stop the air or fluid leak and allow appropriate healing to occur.  New 
approaches are desperately needed. I have devised a new technique based on methacrylated-alginate (Alg-
MA) hydrogels delivered in an easy-to-apply patch formulation that can both seal the affected tissue, as 
well as deliver water-soluble drugs such as fibroblast growth factor 2 (FGF-2) to stimulate repair within the 
pleural lining. 
The proposed pleural sealant patch, is fabricated 
through a process of photolithography using an 
oxidized form of methacrylated-alginate, and will 
be delivered in a ready to use dry form, for easy 
storage and application. Alginate, a natural 
polysaccharide derived from seaweed, is an ideal 
material for this application, as it is easily modified 
to add functionality such as crosslinking to form a 
hydrogel (through methacrylation) or increased 
adhesion to the tissue (through oxidation). The 
dried patch can simply be cut to desired size, 
applied to moist tissue, and exposed to visible light to crosslink and adhere the patch to the pleural surface. 
Promising preliminary results show that the Alg-MA patch is capable of withstanding pressures of 20 cm 
H2O after being applied to a punctured mouse lung. The proposed project focuses on the optimization and 
efficacy testing of the pleural sealant patch to both seal leaks and heal tissue, using both mechanical 
testing, as well as ex vivo, and in vivo studies. 
Specific Aim 1: Determine how the physical properties of Alg-MA hydrogels impact their capacity to 
seal a pleural leak. Alginate will be chemically oxidized to encourage tissue adhesion. We will examine 
the effect of oxidation and degree of methacrylation on physical properties including burst pressure, 
adhesive strength, and cohesive strength. We will verify adhesion and seal formation immediately 
following injury using excised mouse lungs in an ex vivo lung pleural wound model and lung volume 
measurements. 
Specific Aim 2: Determine how Alg-MA hydrogel properties affect their capacity for dynamic 
mechanical stability and controlled release of drugs. Drug release rates are controllable via the degree of 
crosslinking and encapsulation technique. We will develop hydrogel blends with methacrylated-hyaluronan 
to optimize degradation, which further controls release rate. To stimulate wound healing, FGF-2, known to 
stimulate lung tissue wound healing, will be encapsulated within microspheres to protect the drug. We 
expect the degradation rate and rate of drug release to depend on molecular weight, degree of modification, 
and polymer constituents. We will investigate how physical (mass loss, swell ratio) and mechanical 
properties (dynamic elasticity), and drug release rates change over time with different formulations. 
Specific Aim 3: Assess the ability of drug-eluting Alg-MA hydrogels to repair damaged pleural tissue.  
As proof of concept, we will determine the ability of the optimized Alg-MA hydrogels with or without 
FGF-2-containing microspheres to repair pleural leaks in an in vivo rat model of lung collapse. Relevant 
endpoints include durability of repair, maintenance of lung volume, ex vivo burst pressure, and histological 
images.
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APPENDIX XIV: NIH T32 TRAINEE PROGRESS REPORT 2015 
 
Vermont Lung Center NIH T32 Multidisciplinary Training in Lung Biology 
Predoctoral Trainee: Spencer L. Fenn 
Mentor: Rachael A. Oldinski 
 
Mr. Fenn is a fourth year predoctoral fellow in the cross-disciplinary 
bioengineering program working under the advisement of Dr. Rachael A. Oldinski and 
has been training on the Vermont Lung Center grant since January 2015. 
 
Project Summary: 
 
 The primary objective of the Oldinski lab is to develop novel 
biocompatible materials for use in tissue engineering/regeneration and drug delivery 
applications. This multidisciplinary work focuses primarily on the engineering and 
chemical manipulation of polymeric materials to achieve varied physical and mechanical 
properties to suit diverse medical applications. The work of Mr. Fenn is dedicated to the 
use of polysaccharide-based hydrogels as a surgical sealant, 3-dimensional tissue 
scaffold, and also as intracellular drug delivery vehicles. 
 Alginate, a biocompatible polysaccharide sustainably derived from 
brown algae, and hyaluronan, a similar molecule found ubiquitously throughout the 
human body, serve as the base materials for Mr. Fenn’s work. Chemical modifications 
such as methacrylation are performed to allow for covalent and physical crosslinking 
between adjacent polysaccharide chains forming hydrogels which can be used to seal 
damaged tissue, act as a scaffold to encourage tissue growth, or encapsulate drug 
molecules for therapeutic release. 
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 During the past year of training under the T32, Mr. Fenn has been 
highly involved in the development of a novel alginate-based tissue sealing bandage 
which is intended to seal punctured lung tissue, restoring lung function after collapse. 
The primary objective of this work is to improve upon the current standard of care for 
lung collapse which includes insertion of a chest tube, suturing and/or intentional 
chemical/mechanical irritation of the surrounding tissues to induce inflammation 
(pleurodesis). The alginate-based bandage has been shown to successfully adhere and 
seal excised and punctured mouse and rat lungs, restoring lung pressures to physiological 
norms. As a means of higher throughput analysis of modified bandages, a burst pressure 
device was developed and utilized to assess pressures required to induce failure of the 
bandages and the mechanisms of failure (delamination, or material failure). This data was 
then utilized to inform further chemical modifications of the alginate material to increase 
adhesion and elasticity, improving performance on lung tissues. 
 Mr. Fenn was also involved in the development of a novel shear-
thinning, and thermo-responsive alginate-based hydrogel for injectable tissue engineering 
applications. This material has the ability to flow like a liquid at room temperatures and 
when shear forces are applied, allowing for easy application via a syringe, but quickly 
crosslinks to form a solid gel when exposed to temperatures above 34°C (e.g. body 
temperature). The implications of these properties are vast, with potential applications in 
tissue engineering and drug delivery. 
 Methacrylated alginate was also utilized my Mr. Fenn to develop dual-
crosslinked sub-microparticles for intracellular chemotherapeutic delivery. Previous work 
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in the Oldinski lab has shown that many cell types readily internalize alginate sub-
microparticles via the endocytosis pathway, and subsequently they have shown 
successful intracellular delivery of growth factors to induce stem cell differentiation. Mr. 
Fenn utilized two crosslinking techniques to prolong the release profile of a 
chemotherapeutic drug (doxorubicin) by tightening the polymer network structure 
(reducing diffusive release), allowing sufficient time for human lung epithelial carcinoma 
cells (A549) to internalize the particles (confirmed by flow cytometry and microscopy). 
His work shows that lower doses of chemotherapeutic drug can be utilized with increased 
efficacy when delivered intracellularly as compared to drug dosed in cell culture media. 
Further work focused on the use of these particles to treat cancer resistant cell lines, as 
well as inducing preferential internalization by cancer cells is currently being investigated 
within the Oldinski Lab. 
Publications: 
 
Fenn, SL, Miao, T, Scherrer, R, Oldinski, R. A.. "Dual-Cross-Linked Methacrylated 
Alginate Sub-Microspheres for Intracellular Chemotherapeutic Delivery." ACS 
Applied Materials & Interfaces. (Accepted, 2016)) 
 
Fenn SL, Charron PN, Oldinski RA. “Mechanical Properties and Failure Analysis of 
Visible Light Crosslinked Alginate-Based Tissue Sealants.” Journal of the Mechanical 
Behavior of Biomedical Materials. (Accepted, 2015) 
 
Miao T, Fenn SL, Charron PN, Oldinski RA. "Self-Healing and Thermo-Responsive 
Dual-Crosslinked Alginate Hydrogels based on Supramolecular Inclusion 
Complexes." Biomacromolecules. (Accepted, 2015)  
 
Fenn SL, Oldinski RA. "Visible light crosslinking of methacrylated hyaluronan 
hydrogels for injectable tissue repair." Journal of Biomedical Materials Research B 
Applied Biomaterials. (Accepted, 2015).  
 
Wagner, DE, Fenn, SL, et al. "Design and Synthesis of an Artificial Pulmonary Pleura 
for High Throughput Studies in Acellular Human Lungs." Cell Mol Bioeng. (2014). 
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Accepted Abstract Submissions in 2015: 
 
Fenn SL, Miao T, Scherrer R, Oldinski RA. “Intracellular Delivery of Bioactive 
Chemotherapeutic Using Dual-Crosslinked Alginate Sub-Microparticles.” Materials 
Research Society. Boston, MA. (2015) 
 
Fenn SL, Miao T, Krementsov DN, Oldinski RA. “Dual-crosslinked Alginate Sub-
microspheres for Targeted Immunotherapy.” Materials Research Society. Boston, MA. 
(2015) 
 
Miao T, Fenn SL, Charron PN, Oldinski RA. “Self-Healing and Thermo-Responsive 
Alginate Hydrogels for Biomedical Applications.” Biomedical Engineering Society. 
Tampa FL (2015) 
 
Charron PN, Poniz A, Fenn SL, Weiss DJ, Oldinski RA. “Burst Properties and 
Adhesion Strength of Oxidized Methacrylated Alginate Lung Sealants.” Society for 
Biomaterials. NC. (2015) 
 
Miao T, Fenn SL, Charron PN, Oldinski RA. “Injectable Hydrogel based on 
Supramolecular Inclusion Complexes between Alginate-graft-Cyclodextrin and 
Polypropylene Glycol.” Society for Biomaterials. NC. (2015) 
 
Charron PN, Fenn SL, Oldinski RA. “Optimization of Test Methods and Burst Property 
Characterization of Alginate Hydrogel Lung Sealants.” SB3C. Snowbird, Utah. (2015) 
 
Fenn SL, Charron PN, Weiss DJ, Oldinski RA. “An Alginate-Based Pulmonary Patch 
for Repairing Pleural Injuries.” MRS Chapter Materials Focus Session, UVM. (2015) 
 
 
 
Other Activities: 
 
Mr. Fenn is an active member of several academic societies including Materials Research 
Society (MRS), Society for Biomaterials (SFB), and Biomedical Engineering Society 
(BMES) and has also participated in the Summer Biomechanics Bioengineering and 
Biotransport Conference (SB3C) in 2015. Mr. Fenn is current President of the University 
of Vermont Chapter of the Materials Research Society, as well as Vice-Chairman of the 
Board of Directors for a local AIDS Service Organization (ASO). Additionally, Mr. Fenn 
is currently enrolled in the University of Vermont Graduate Teaching Program 
 
